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1 Introduction
1.1 Cancer and Metastasis
In 2000 Hanahan and Weinberg determined six hallmarks of cancer, which are required for 
multistep  development  of  tumors:  sustaining  proliferative  signaling,  evading  growth 
suppression, resisting programmed cell  death, enabling replicative immortality,  inducing 
angiogenesis, activating invasion and metastasis (Hanahan and Weinberg, 2000). During 
the  past  decade,  remarkable  discoveries  and  progress  towards  understanding  each 
hallmark of cancer have been made. Defining tumors not only as masses of proliferating 
cancer cells,  but as complex tissues composed of a variety of  cell  types implicated in 
mutual interaction (Figure 1.1.1), led to revision and modification of formulations originally 
postulated. Therefore, in 2011 Hanahan and Weinberg, next to existing six hallmarks of 
cancer, included four new hallmarks: avoiding immune destruction, genome instability and 
mutation,  deregulating  cellular  energetics  and  tumor-promoting  inflammation  (Hanahan 
and Weinberg, 2011). 
Figure  1.1.1  Tumor-stroma interactions  in  primary  tumor  development.  a  For  intravasation  of 
cancer cells into the bloodstream the presence of perivascular macrophages and BMDCs is necessary.  
Macrophages  and  BMDCs  supply  the  surrounding  tissue  with  proteases  for  vascular  basement 
membrane degradation and endothelial  cell  contact  disruption,  which  is  required for  tumor  cells  to 
escape into the bloodstream, b Migration of cancer cells is accompanied with cross-talk between tumor 
cells,  macrophages,  fibroblast  and  pericytes.  Cancer  cells  produce  CSF1,  which  stimulates 
macrophages to secrete growth factors like e.g. EGF. Furthermore, cancer cells express CXCR4 on 
their  surface,  which is  activated by CXCL12 produced by fibroblasts  and pericytes.  This  cross-talk 
induces tumor cell movement towards macrophages, fibroblasts and pericytes (marked with dashed 
arrows); CSF1 - colony stimulating factor 1,  CXCR4 - C-X-C chemokine receptor 4, CXCL12 - C-X-C 
chemokine 12,  EGF -  epidermal growth factor,  EGFR -  epidermal growth factor receptor,  CSF1R - 
colony-stimulating factor 1 receptor,  BMDC  -  bone marrow derived cells.  Picture was adopted from 
Joyce and Pollard, 2009.
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Most cancer cells fail to undergo metastasis because of one or more deficiencies during 
this process (Fidler, 2003). Metastasis-competent cancer cells should be able to invade 
locally  through  surrounding  extracellular  matrix,  intravasate  into  the  lumina  of  blood 
vessels, survive the rigors of transport through the vasculature and arrest at distant organ 
sites. At distant organs they have to extravasate into the parenchyma, initially survive in 
these  foreign  microenviroments  in  order  to  form  micrometastasis  and  reinitiate  their 
proliferative capability  at  metastatic  sites (Valastyan and Weinberg,  2011).  As the  end 
product of this multistep process – metastasis at distant organ, takes place.
Stephen Paget,  the creator of  the „seed and soil“  hypothesis,  postulated in 1889 that 
metastasis does not occur by chance, but that rather certain tumor cells with metastatic 
activity  („seed“),  choose a  specific  organ („soil“)  for  the growth-enhancing milieu.  This 
hypothesis  survived  until  today,  with  more  profound  explanations  why  metastasis-
competent  cells  have  particular  preferences  towards  specific  tissues.  Nowadays,  it  is 
known  that  gene  expression  in  certain  organs  can  guide  cancer  cells  to  metastatic 
colonization. Breast cancer cells e.g.  metastasize specifically to the lungs (Minn et al., 
2005) or the liver (Tabaries et al., 2011). 
Metastatic seeding can be enhanced by the action of primary tumors, that secrete factors, 
which „prepare“ distant organs for upcoming of cancer cells, thus forming a pre-metastatic 
niche  (Kaplan  et  al.,  2005).  Kaplan  and  colleagues  demonstrated  that  Lewis  Lung 
Carcinoma (LLC) cells, that metastasize to the lungs and occasionally to the liver, and B16 
melanoma cells, which possess a more widely disseminating metastatic potential, secrete 
vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). VEGF and 
PlGF, produced by the primary tumor, can attract bone marrow-derived haematopoietic 
progenitor cells (BMDCs) via engagement of vascular endothelial growth factor receptor 1 
(VEGFR1). BMDCs that are VEGFR1+, can home to tumor-specific pre-metastatic sites 
and form cellular clusters before the arrival of tumor cells. 
1.2 A Disintegrin and Metalloprotease 17 (ADAM17) 
ADAM17  was  characterized  and  cloned  in  1997  as  a  protease  responsible  for  the 
cleavage of the membrane bound form of tumor necrosis factor-alpha, proTNF-α (Black 
and White, 1997), it was there initially termed TNF-α converting enzyme (TACE). It belongs 
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to  the  family  of  metalloproteases  with  high  sequence  homology  to  the  snake  venom 
metalloproteinases (SVMPs) (Blobel, 1997).
ADAM17 is  a  type I  transmembrane protein  with  a  domain structure  (Figure  1.2.1).  It 
consists  of  pro-domain,  catalytic,  disintegrin,  membrane proximal,  transmembrane and 
cytoplasmic domains. Each domain has unique functions. ADAM17 pro-domain acts as an 
inhibitor of the protease activity and it is only present when ADAM17 is in an inactive state 
(cleavage of pro-domain is regulated by furin protease in late Golgi compartment). The 
catalytic  domain  contains  the  Zn2+-binding  consensus  motif  H-E-X-G-H-X-X-G-X-X-H-D 
involved in coordinating Zn2+ with histidine residues and creating the active site of  the 
enzyme (Stöcker et al., 1995). A disintegrin domain is important for the interaction with 
integrins while membrane proximal domain is necessary for the recognition of substrates 
and dimerization. The transmembrane domain is responsible for localization in the lipid 
rafts.  Cytoplasmic  domain  is  necessary  for  subcellular  localization,  trafficking  and 
activation via phosphorylation (Scheller et al., 2011). 
Figure 1.2.1 ADAM17 domain structure. ADAM17 has six domains, each with unique functions.  
Picture was modified from Scheller et al., 2011.
ADAM17 has emerged as a sheddase with an extremely broad substrate range. ADAM17 
generates soluble proteins from their membrane-bound precursors in a process termed 
protein ectodomain shedding. ADAM17 is responsible for the membrane release of TNF-α 
and its receptors:  tumor necrosis factor alpha receptor I  and II  (TNFR  I  and TNFR II). 
Furthermore, ADAM17 is responsible for the proteolytic release of epidermal growth factor 
receptor  (EGFR)  ligands  like  e.g.  amphiregulin  (AR),  transforming  growth  factor-alpha 
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(TGF-α), heparin binding-epidermal growth factor (HB-EGF) (Sahin et al., 2004). Soluble 
forms of these proteins have a pivotal role in cell development, inflammation, migration, 
cell proliferation, angiogenesis and invasion (Figure 1.2.2). 
Figure  1.2.2  The implication of  ADAM17 in  inflammatory  and proliferatory  stimuli.  ADAM17 
releases  soluble  ligands  from  the  membrane  surface,  in  the  process  denoted  as  „ectodomain 
shedding“. sTNF-α activates TNFR  I, and induces activation and translocation of transcription factor NF-
κB to the nucleus  where it activates transcription of genes implicated in inflammation. EGFR can be 
activated with different ligands like AR, TGF-α, HB-EGF. Activation of EGFR induces cell survival and 
proliferation via Erk kinase signaling. The generation of sIL-6R is a prerequisite for IL-6 trans-signaling 
(explained in detail in section 1.4). IL-6 trans-signaling activates phosphorylation and dimerization of 
STAT 3 proteins which are important for cell proliferation; ADAM17 - A Disintegrin and Metalloprotease 
17, sTNF-α - soluble tumor necrosis factor alpha, TNFR I - Tumor Necrosis Factor Receptor I, NF-κB - 
Nuclear  Factor  kappa  B,  sIL-6R  -  soluble  interleukin-6  receptor,  STAT3  -  Signal  transducer  and 
activator of transcription 3,  EGF - epidermal growth factor,  TGF-α - transforming growth factor alpha, 
HB-EGF - heparin binding epidermal growth factor, EGFR - epidermal growth factor receptor, Erk 1/2 - 
extracellular-signal-regulated kinases.
ADAM17 deficient mice (ADAM17-/-) showed embryonic lethality between embryonic day 
17.5 and the first day of birth (Peschon et al., 1998). ADAM17 deficient embryos displayed 
defects reminiscent  of  those in TGF-α deficient  mice,  with additional  defects similar to 
those caused by the lack of EGFR. 
Chalaris and colleagues succeeded in generating viable mice with barely detectable levels 
of ADAM17 in all tissues (Chalaris et al., 2010). They introduced a novel strategy called 
exon-induced translational stop (EXITS), which is based on the insertion of an artificial 
exon in  the  ADAM17 gene.  This  extra  exon,  named exon 11a,  was inserted between 
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exon 11 and exon 12. The inserted exon contained an in frame translational stop codon 
and  it  was  flanked  by  splice  donor/acceptor  sites,  which  slightly  deviated  from  the 
canonical consensus sequence. Homozygous mice, denoted as ADAM17ex/ex mice (named 
ex/ex for the  EXITS strategy), expressed only  ~5% of ADAM17 protein in all cell types 
compared to wild type mice. ADAM17ex/ex mice had macroscopically visible eye and hair 
defects,  reminiscent  to  TGF-α knock out  mice.  Interestingly,  ADAM17ex/ex mice showed 
abrogated generation of soluble TNF-α and significantly reduced shedding of TNFR  I and 
TNFR II, indicating impaired ADAM17 activity. 
1.3. ADAM17 in cancer and metastasis
Over  the  last  few years  ADAM17 has  been  associated  with  tumorigenesis  and  tumor 
progression. A very common and vastly investigated type of human lung cancer is Non-
Small Cell Lung Cancer (NSCLC). NSCLC comprises any type of epithelial lung cancer 
except small cell lung carcinoma (SCLC). NSCLC is the leading cause of cancer-related 
deaths in the United States and Europe with very limited treatment options.  The most 
common types of NSCLC are adenocarcinoma, large cell carcinoma and squamous cell 
carcinoma.  In  a  recent  study,  Ni  and  colleagues  could  demonstrate  that  ADAM17 
expression  in  NSCLC correlated  with  patients  poor  prognosis  (Ni  et  al.,  2013).  They 
performed  quantitative  real  time  PCR  to  asses  the  ADAM17  mRNA expression  from 
tissues of 124 patients with clinicopathologically characterized NSCLC. Furthermore, they 
analyzed  the  expression  of  ADAM17  by  immunohistochemistry.  They  discovered  that 
ADAM17 mRNA and protein expression levels in NSCLC tissues were both significantly 
higher than those in non-cancerous tissues. Interestingly, Ni and colleagues demonstrated 
that  high expression of  ADAM17 significantly  correlated  with  tumor  size,  tumor  grade, 
lymph node metastasis, aggressive progression and poor prognosis. They suggested that 
ADAM17  could  be  an  important  molecular  marker  for  predicting  carcinogenesis, 
progression and prognosis of NSCLC.
1.3.1 The impact of ADAM17 on epidermal growth factor receptor (EGFR)
All  EGFR  ligands  are  produced  as  membrane-associated  molecules  that  require 
proteolytic processing by ADAM17 and A Disintegrin and Metalloprotease 10 (ADAM10) for 
the generation of the active forms. Upon binding of its active ligand, EGFR dimerizes and 
becomes activated. EGFR dimerization stimulates its intrinsic intracellular tyrosine kinase 
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activity,  which  leads  to  its  autophosphorylation,  and  subsequently  to  downstream 
activation  of  several  signal  transduction  cascades.  Principally  the  cascades  are  the 
MAPK/Erk (Mitogen-activated protein kinases/Extracellular signal-regulated kinases),  Akt 
(also known as Protein kinase B) and JNK (c-Jun NH(2)-terminal kinase) pathways. These 
pathways are implicated in cell proliferation, survival, migration and invasion. 
EGFR activation  has  been  implicated  in  cancer  development,  growth  and  metastasis 
(Olayioye et al., 2000). Shedding of TGF-α was necessary for tumor formation in a model 
of ovarian cancer (Borrell-Pages et al., 2003). Namely, Borell-Pages and colleagues could 
demonstrate that the transmembrane form of TGF-α (proTGF-α) interacted with, but did 
not activate the EGFR. They made a series of proTGF-α deletion constructs affecting the 
ADAM17 cleavage site and stably transfected these constructs in Chinese hamster ovary 
(CHO) cells. As a control for unimpaired ADAM17 shedding, they stably transfected CHO 
cells with a construct containing wild type proTGF-α. Interestingly, they demonstrated that 
over-expression of  wild  type proTGF-α in CHO cells  allowed vigorous growth  of  CHO 
xenografts  in  nude  mice.  In  contrast,  deletion  constructs  in  CHO  cells  resulted  in 
significantly reduced tumor growth of CHO xenografts in nude mice. They demonstrated 
that ectodomain shedding of proTGF-α by ADAM17 is required for activation of the EGFR 
and  for  maximal  tumor  growth  in  vivo,  thus  indicating  a  crucial  role  for  ADAM17  in 
tumorigenesis.
1.3.2  The implication of ADAM17 in Notch signaling
One of evolutionary the most conserved pathways involved in cell development and cell  
self-renewal is Notch signaling. It has been reported that Notch signaling participates in 
tumor-stroma and tumor-endothelium interactions  in  primary  tumors  and  in  metastasis 
(Pannuti et al., 2010). ADAM17, next to ADAM10, has a prominent role in activation of  
Notch signaling (Brou et al., 2000). There are four transmembrane Notch receptors (Notch-
1, Notch-2, Notch-3 and Notch-4) and five transmembrane ligands (Delta-like [DLL] 1, DLL 
2, DLL 3, DLL 4, Jagged-1 and Jagged-2).
 
Notch  receptors  are  synthesized  as  precursor  proteins,  which  are  subjected  to  three 
proteolytic cleavages. In signal-receiving cells, Notch precursor proteins are processed in 
the  trans-Golgi  apparatus  by  furin-like  convertases  to  generate  a  mature receptor. 
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This  cleavage  is  marked  as  S1  cleavage  (Figure  1.3.1).  The  mature  receptor  is  a 
heterodimer consisting of Notch extracellular and Notch transmembrane parts. The mature 
receptor  is  then  translocated  to  the  cell  membrane  where  it  can  be  engaged  with  
membrane associated ligands from the signal-sending cell. Upon binding of a ligand to the 
Notch receptor, S2 cleavage occurs. 
Interestingly, ADAM10 cleaves Notch in ligand-dependent activation, while ADAM17 can 
cleave Notch receptor in ligand-independent activation (Bozkulak et al., 2009). Bozkulak 
and colleagues demonstrated that ADAM17 cannot cleave Notch-1 in response to ligand. 
Performing coimmunoprecipitation, they demonstrated that ADAM17 does not interact with 
endogenous Notch-1, explaining that perhaps ADAM17 and Notch-1 occupy distinct cell 
surface microdomains.  However,  they were  able to  coimmunoprecipitate ADAM17 with 
ectopically expressed Notch-1. Furthermore, they could show that ADAM17 activation of 
ectopically  expressed Notch-1 did  not  require ligand interaction as well  as ectodomain 
shedding, thus excluding the possibility that ADAM17 cleaves Notch-1 at the cell surface. 
Although it was unclear where in the cell ADAM17 cleaves and activates Notch-1, they 
speculated  that  ADAM17  and  Notch-1  accumulate  at  high  levels  intracellularly.  This 
accumulation could enhance interactions between these two proteins, and subsequently 
activate Notch-1 receptor. 
After  S2  cleavage,  the  extracellular  part  of  Notch  receptor  bound  to  its  ligand  is 
endocytosed in the signal-sending cell and degraded. S3 cleavage, which is mediated by 
γ-secretase  at  the  plasma  membrane,  results  in  the  release  of  the  active  Notch 
Intracellular  Domain  (NICD).  NICD  translocates  into  the  nucleus  where  it  recruits 
transcriptional  regulators,  and forms the “Notch transcriptional  complex”  leading to  the 
transcription  of  genes  like  e.g.  Hairy/Enhancer  and  Split  1  or  5  (Hes  1,  Hes  5)  or 
Hairy/enhancer-of-split related YRPW motif like protein 1 (Hey1). This signaling is known 
as classic Notch signaling. 
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Figure  1.3.1  Classic  Notch  signalling.  Notch  precursor  is  processed  in  the  Golgi  apparatus  to 
generate a mature form of Notch (S1 cleavage). After S1 cleavage, mature Notch is translocated to the 
cell surface. After binding a ligand, extracellular part of Notch receptor is cleaved by ADAM10/ADAM17 
(S2 cleavage). Intracellular NICD is generated through the third (S3) cleavage by γ-secretase. NICD 
forms a complex with the transcriptional regulators Co-A, MAM and CSL, and acts as transcription 
factor;  NICD -  Notch Intracellular Domain,  ER -  Endoplasmic Reticulum,  Co-R – transcriptional  co-
repressors,  CSL -  DNA-binding  protein,  MAM -  co-activator.  Picture  was  adopted  from Kopan  and 
Liagan, 2009.
Baumgart and colleagues pointed out that ADAM17 contributes to tumor growth via Notch-
1-mediated up-regulation of EGFR expression in NSCLC (Baumgart et al., 2010). They 
demonstrated that ADAM17 knock down in NSCLC cells abrogated tumor growth in nude 
mice.  Interestingly,  they  managed  to  identify  Notch-1  signaling  as  the  main  pathway 
responsible for such significant tumor reduction in mice. Moreover, knock down of Notch-1 
in tumor cells lead to reduced EGFR expression. They could show that inhibition of Notch-
1 and ADAM17, but not of EGFR, resulted in tumor cell death. Until  now, targeting the 
EGFR  in  NSCLC  was  considered  to  be  a  promising  therapy.  Unfortunately,  the 
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majority  of  NSCLC patients  do  not  respond  to  EGFR targeted  therapy.  The  study  of 
Baumgart et al.  for the first time demonstrated that ADAM17 mediated Notch signaling 
contributes to the expression of EGFR. This finding marked ADAM17 and Notch-1 as a 
promising targets for the treatment of NSCLC.
In  a  recent  publication  Lu  and  colleagues  could  demonstrate  that  for  promotion  of 
colorectal  cancer metastasis angiocrine Notch signaling is necessary (Lu et al.,  2013). 
Hereby, the soluble Notch ligand Jagged-1 is liberated by ADAM17 from the surface of 
endothelial  cells.  Soluble Jagged-1 can interact  with Notch receptor  on the surface of 
cancer cell and stimulate γ-secretase-mediated release of NICD into the cytoplasm. NICD 
activates the transcription of genes necessary for the transformation of cancer cells into 
cancer-stem cells (Figure 1.3.2).  Cancer-stem cells (CSCs) posses properties like self-
renewal,  which drives tumorigenesis and resistance to cell  death, which leads towards 
tumor progression. This finding marked ADAM17 as a potential target for eradication of  
CSCs.
Figure 1.3.2 Angiocrine Notch signaling. Extracellular part of Jagged-1 is released from the surface 
of endothelial cells by ADAM17 mediated cleavage. Soluble Jagged-1 can interact with Notch receptor 
on  the  surface  of  cancer  cell  and  activate  transcription  of  Notch  genes  e.g.  Hes-1  which  drives 
transformation of cancer cell  to cancer stem cell  (CSC);  NICD  -  Notch Intracellular Domain,  CSL  - 
transcriptional repressor, Hes-1 - hairy and enhancer of split-1. Picture taken from Lu et al., 2013.
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1.4 Nuclear factor-kappa B (NF-κB) in cancer 
According  to  Weinberg  and  Hannahan  there  are  ten  hallmarks  of  cancer  and  the 
transcription factor NF-κB can affect six of them through the transcriptional activation of 
genes  associated  with  angiogenesis,  metastasis,  tumor  promotion,  inflammation, 
suppression of apoptosis and cell proliferation (Baud and Karin, 2009). NF-κB activation 
can induce chemokine and cytokine expression like e.g. CXCL1, CXCL8, TNF-α, IL-6 and 
VEGF, which have been implicated in angiogenesis, or ICAM-1 and VCAM-1, which are 
necessary for cell adhesion. NF-κB can support tumor promotion via induction of matrix 
metalloprotease 2 (MMP2) and MMP9, which influence degradation of extracellular matrix 
and  promotion  of  metastasis.  There  are  different  mechanisms  of  NF-κB  activation  in 
cancer and some of them will be discussed.
The  innate  immune  system is  evolutionary  conserved  and  represents  the  first  line  of 
defense in host protection against invading microbial pathogens. Toll-like receptors (TLR) 
can elicit innate immune response after recognition of microbial components. TLRs are 
expressed on various immune cells,  such as  macrophages,  neutrophils,  dendritic  and 
epithelial cells. TLRs are transmembrane proteins with N-terminal extracellular leucine-rich 
repeats,  which  are  responsible  for  the  recognition  of  pathogen-associated  molecular 
patterns  (PAMPs).  The family  of  TLRs has  13 members  with  each member  detecting 
distinct PAMPs e.g. lipopolysaccharide (LPS) is recognized by TLR4, lipoproteins by TLR2, 
flagelin by TLR5. After recognition of PAMPs, TLRs recruit a set of adaptor proteins in the 
cytoplasm,  and trigger  downstream signaling cascades leading to  activation  of  NF-κB. 
Next to the induction of transcription of pro-inflammatory cytokines and chemokines, NF-
κB influences the upregulation of co-stimulatory molecules essential for T-cell activation 
(Kawai et al., 2007).
Interestingly, in some cases TLRs can be activated in response to tumor cells. 
In a recent report Kim and colleagues demonstrated activation of a TLR2/6 heterodimer in 
response to factors that are secreted by cancer cells (Kim et al., 2009).  They collected 
serum free conditioned media from several murine cancer cell lines, placed them to bone 
marrow derived macrophages (BMDMs) and assessed the production of pro-inflammatory 
cytokines such as TNF-α, IL-6 and IL-1β. Media from two cancer cell lines, Lewis Lung 
Carcinoma (LLC) and the breast cancer (4T1) cell line, stimulated BMDMs and induced 
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secretion of TNF-α and IL-6. Interestingly, Kim and colleagues identified several proteins, 
which are components of the extracellular matrix (ECM) in conditioned medium of LLC 
cells: versican V1, laminin β1, trombospondin 3 and pro-collagen type III α1. To investigate 
the role of these ECM proteins in the metastatic potential in vivo, they generated stable 
knock  down  LLC  cells  with  shRNA specific  to  detected  ECM  components  from  the 
conditioned medium and injected them into wild type mice. Silencing of versican V1 in LLC 
cells, resulted in a significant reduction of tumor growth, while silencing the expression of 
other  ECM  components  did  not  alter  tumor  growth.  To  determine  the  versican  V1 
mechanism of action, they assessed the production of IL-6 upon stimulation of  TLR2-/-, 
TLR3-/-, TLR4-/- and TLR9-/- BMDMs with LLC serum free conditioned medium. They were 
able to show that exclusively TLR2-/- BMDMs did not produce IL-6, thus indicating that IL-6 
production is fully dependent on TLR2 activation. To investigate whether TLR2 signaling 
contributes to LLC induced metastasis, Kim and colleagues injected wild type LLC cells 
into  TLR2-/-  mice.  They  were  able  to  confirm  greater  survival  and  a  significant  tumor 
reduction in TLR2-/- lungs compared to control mice. Interestingly, TNF-α-/- mice displayed a 
markedly reduced mortality and tumor burden after LLC injection as compare to IL-6 -/- and 
wild type mice. This work indicated that TLR2 and TNF-α but not IL-6 from the host are 
crucial for lung metastasis.
Interestingly, Pirinen and colleagues analyzed expression of versican in tumor stroma and 
in cancer cells from 212 patients suffering from NSCLC (Pirinen et al., 2005). They could 
show that high stromal staining for versican correlated with tumor recurrence, lymph node 
metastasis and poor prognosis, while the expression of versican in normal lung tissue was 
rather low. 
Taking into consideration that LLC cells produce pro-metastatic factors e.g. versican V1, 
and  that  expression  of  versican  in  NSCLC  in  the  stroma  strongly  correlates  with 
recurrences  and  poor  prognosis  in  patients  (Isogai  et  al.,  2005),  the  LLC  model  of 
experimental  metastasis  can  give  insight  into  molecular  mechanisms  of  lung  cancer 
development and metastasis.
TNF-α  was  identified  in  1975  as  an  endotoxin-induced  glycoprotein,  which  caused 
haemorrhagic necrosis  of  sarcomas that  had been transplanted into mice (Carswell  et  
al.,1975).  TNF-α  is  produced  predominantly  by  activated  myeloid  cells  and 
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T-lymphocytesas as a membrane bound 26 kDa protein, pro-TNF-α, which is cleaved from 
the membrane surface mainly  by ADAM17.  sTNF-α binds as a homotrimer  to  TNFR  I 
(Figure 1.4.1), while membrane  bound TNF-α binds and activates TNFR II (Grell et al., 
1995). TNFR I is expressed by all  tissue while TNFR  II  is mostly expressed in immune 
cells. The binding of TNF-α to its receptors causes the activation of two major transcription 
factors,  NF-κB and AP-1.  NF-κB is regulated primarily  by phosphorylation of  inhibitory 
proteins,  the  IκBs,  which  retain  NF-κB  in  the  cytoplasm  of  non-stimulated  cells.  In 
response to TNF-α and other agonists, the IκBs are phosphorylated by the IκB kinase 
(IKK) complex, resulting in their ubiquitination, degradation and , subsequently, in nuclear 
translocation  of  the  freed  NF-κB.  AP-1  represents  a  complex  of  transcription  factors 
consisting of Jun, Fos and ATF subunits.
Figure  1.4.1  Complexity  of  TNF-α  signaling.  Soluble  TNF-α  (sTNF-α)  is  generated  by  ADAM17 
mediated cleavage. To be able to interact with and activate TNFR I, sTNF-α has to form homotrimers. 
Active TNFR I leads to downstream activation of several kinases which induce phosphorylation of NF-
κB  inhibitory  subunit  IκB,  thus  releasing  NF-κB.  Active  NF-κB  translocates  into  the  nucleus  and 
activates transcription of genes; ADAM17  -  A Disintegrin and Metalloprotease 17,  TNFR I  -  Tumor 
Necrosis Factor Receptor I, DD - death domain, TRADD - TNFR I associated death domain containing 
protein,  TRAF2 -  TNFR associated factor  2,  RIP -  receptor  interacting protein,  MEKK1 -  mitogen-
activated  protein  kinase kinase kinase 1,  NF-κB -  Nuclear  Factor  kappa B,  NIK -  NF-κB-inducing 
kinase, IKK - IκB kinase,  IκB - inhibitor of NF-κB. Picture was modified from Palladino et al., 2003. 
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Upon stimulation with TNF-α, various Mitogen activated protein kinases (MAPKs) enter the 
nucleus  to  phosphorylate  DNA-bound  transcription  factors,  like  Jun,  and  induce  AP-1 
activity. The TNF-α promoter itself contains NF-κB and AP-1 binding sites and is a subject  
to positive autoregulation. TNF-α can mediate inflammation in the immune system, which 
is therapeutic if the inflammation is acute, short-term without permanent tissue damage. If 
the inflammation is chronic or long-term, it can cause a damage that is more likely to lead 
to chronic disease such as cancer. Therefore, TNF-α can be defined as a „double-edged 
sword“ cytokine. 
IL-6 is a multifunctional cytokine initially found to be a B-cell differentiation factor which 
induces immunoglobulin production (Muraguchi et al., 1988). Nowadays, it is known that 
IL-6 regulates immune response, acute phase response and inflammation. IL-6 is secreted 
by  various  lymphoid  cell  types  such  as  T-cells,  B-cells,  macrophages  and  monocytes 
(Kishimoto et al, 1995) and its production can be induced by NF-κB activation. On target 
cells, IL-6 in a complex with membrane bound IL-6R interacts with two gp130 molecules 
and  induces  activation  of  JAK/STAT (Janus  kinase/Signal  transducer  and  activator  of 
transcription)  pathway  (Rose-John,  2012). This  is  called  IL-6  classic  signaling  (Figure 
1.4.2). Only few cell  types like hepatocytes, some leukocytes and some epithelial cells 
express membrane bound IL-6R, while gp130 molecule is expressed by all  cells of the 
body. Cells, which do not express IL-6R, are unresponsive to IL-6 alone, since gp130 has 
no affinity to IL-6, but only to its complex with IL-6R. Interestingly, the soluble isoform of 
the  IL-6R  can  be  generated  by  alternative  splicing  or  by  proteolytic  cleavage  of  the 
membrane-bound  precursor.  For  the  constitutive  shedding  of  IL-6R  appears  to  be 
responsible  ADAM10,  while  ADAM17  accounts  for  the  stimulated  shedding  of  IL-6R 
(Matthews et al.,  2003).  sIL-6R can associate with IL-6 and form IL-6/sIL-6R complex, 
which can interact with gp130 molecule, induce its dimerization and subsequently activate 
JAK/STAT pathway. This is called IL-6 trans-signaling (Figure 1.4.2). IL-6 trans-signaling 
drastically enlarges the spectrum of IL-6 target cells.
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Figure 1.4.2 IL-6 classic and trans-signaling.  IL-6 classic signaling is limited to hepatocytes, some 
leukocytes and some epithelial cells. For IL-6 classic signaling engagement of membrane bound IL-6R 
is  required.  Complex  between  IL-6  and  mIL-6R  induces  dimerization  and  activation  of  signal 
-transducing gp130 molecules. IL-6 trans-signaling can be activated in all cell types in the body and it  
requires  engagement  of  soluble  IL-6R.  Complex  between  IL-6  and  sIL-6R  can  activate  signaling 
downstream of dimerized gp130 molecules. IL-6 - interleukin 6, sIL-6R - soluble interleukin 6 receptor, 
mIL-6R – membrane bound interleukin-6 receptor, gp130 - glycoprotein 130. Picture was modified from 
Rose-John, 2012.
In a recent publication, Yi and colleagues demonstrated importance of sIL-6R and IL-6 for 
the growth of cancer-stem cells (CSCs) in NSCLC (Yi et al., 2012). They isolated CSCs 
from H460 NSCLC and assessed proliferation rate and production of sIL-6R and IL-6 in 
their  medium,  compared  to  non-CSC.  CSCs  proliferation  compared  to  non-CSCs 
proliferation, was significantly slower. Since the growth rates of CSCs and non-CSCs were 
substantially different, to be able to compare the amounts of produced sIL-6R and IL-6 
from the cell medium, they normalized concentrations of sIL-6R and IL-6 based on the cell 
numbers.  Normalized concentration of sIL-6R was significantly higher in CSCs than in 
non-CSCs medium, while the concentration of IL-6 was the same in the medium of both 
CSCs  and  non-CSCs.  Interestingly,  blocking  IL-6  or  IL-6R  alone,  or  IL-6  and  IL-6R 
together, resulted in diminished growth of CSCs. The authors concluded that targeting of 
IL-6R and  IL-6  would  be beneficial  for  the  development  of  CSC-targeted lung  cancer 
therapies, and suggested that IL-6R can be a potential CSC marker in NSCLC. However, 
authors  did  not  comment  would  the  inhibition  of  ADAM17  or  ADAM10,  as  IL-6R 
sheddases, influence the growth of CSCs.
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1.5 Immune response in cancer and metastasis
The theory of immune surveillance was introduced in the early 1900s by Ehrlich,  who 
hypothesized that one critical function of the immune system was to detect and eliminate 
tumors from the host. Nowadays, it is known that T-cells are one of the crucial components  
of the immune system that can eliminate tumor cells (Toepfer et al., 2011).
T-cells are type of lymphocytes generated in the primary lymph organs: bone marrow and 
thymus.  They  play  a  central  role  in  cell-mediated  immunity.  T-cell  mediated  immune 
response  begins  in  the  secondary  lymph  organs:  spleen,  lymph  nodes  and  lymphoid 
tissues associated with mucosal surfaces. Secondary lymph organs have specialized T- 
cell  rich zones where naïve T-cells are concentrated. T-cells rest in the spleen for few 
hours and in the lymph nodes for about 1 day, before they leave through the lymphatic 
vessels and reach the bloodstream. From the bloodstream T-cells again enter lymphoid 
organs and, if they are not activated there by antigen presenting cells, repeat the cycle or 
they die by neglect.
T-cells  are  activated  via  their  T-cell  receptor  (TCR).  The  TCR  is  a  protein  complex 
consisting  of  ɑβ  heterodimers,  responsible  for  antigen  recognition,  and  Cluster  of 
Differentiation  3  (CD3)  molecules,  involved  in  intracellular  signaling.  CD3  molecules 
consist of several chains ζ, δ, ε and γ, with intracellular immuno-receptor tyrosine-based 
activation motif (ITAMs) which initiates signal transduction.
TCR binds to antigen peptides presented on two major histocompatibility complex class 
molecules (MHCs), MHC class I and MHC class II, on the surface of antigen presenting-
cells. Professional antigen-presenting cells (APCs) are dendritic cells (DC), macrophages 
and B-cells.  T-cells  have several  subsets,  which are distinguished by different  lineage 
markers and functional activities. CD4+ T-cells recognize antigen in the context of MHC 
class  II  molecules,  which  are  expressed  on professional  APCs.  CD4+ T-cells  produce 
cytokines and are marked as helper T-cells. CD8+ T-cells are activated by antigen peptides 
presented in the context of MHC class I molecules, which are expressed on all nucleated 
cells.  Following  the  recognition  of  peptides  presented  by  tumor  cells  in  MHC class  I 
molecules, activated CD8+ T-cells, named cytotoxic T lymphocytes (CTLs), can efficiently 
destroy  cancer  cells  using  one  of  two  major  apoptotic  pathways:  Ca2+ dependent 
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perforin/granzyme-mediated  apoptosis  or  Ca2+-independent  Fas  ligand/Fas-mediated 
apoptosis. Ca2+ dependent apoptosis is mediated by lytic granules, which contain enzymes 
perforin  and  granzyme  B  and  proteoglycan  serglycin  (Figure  1.5.1).  Granules  are 
transported into target cell as one complex in endocytosed vesicle. In the membrane of 
endocytosed vesicle, perforin forms a pore and enables granzyme B to enter the cytosol of  
target  cell  and  induce  apoptosis  in  caspase-dependent  mechanism.  Ca2+-independent 
apoptosis is initiated by binding of Fas molecule (known as CD95) on the target cell via 
Fas ligand (known as CD95L) on the CTL. Fas molecule is a member of TNF-receptor 
family with intracellular death domain, which initiates caspase-dependent apoptosis after 
binding to Fas ligand.
Figure 1.5.1 Cytotoxic T lymphocyte cytotoxicity. Cytotoxicity of CTL cells can be mediated by two 
distinct  pathways.  One  pathway  is  induced  via  secretion  of  perforin,  which  creates  pores  in  the 
membrane of the target cell, and granzyme B, which induces apoptosis of a target cell. The second 
pathway is via interaction of Fas ligand, on CTL cell, with Fas, on a target cell. This interaction induces 
sequential  caspase  activation,  which  leads  to  apoptosis;  TCR –  T  cell  receptor,  MHC  I –  Major 
histocompatibility complex class I,  CTL – cytotoxic CD8+ T-cell,  CD95 – cluster of differentiation 95, 
CD95L – cluster of differentiation 95 ligand. Picture adopted from Nijkamp and Parnham , 2011.
Peptides  presented by MHC class II molecules, play also an important  role in adaptive 
anti-cancer immunity. MHC class II molecules present peptides, which are recognized by 
CD4+ T-cells.  CD4+ T-cells can improve the capacity of DCs to induce CTLs by cross-
linking  the  co-stimulatory  molecule  CD40  on  DCs  with  the  CD40  ligand  (CD40L)  on 
activated CD4+ T-cells. Besides this, activated CD4+ T-cells can significantly boost cellular 
components of the innate immunity, such as macrophages, by enhanced IFN-γ secretion. 
IFN-γ stimulates higher expression of MHC class I molecules on antigen presenting cells 
thus improving the recognition capacity of CD8+ T-cells.
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Despite  ongoing surveillance by T-cells and other components  of  the immune system, 
tumors develop even in presence of an intact immune system and become eventually 
clinically detectable. 
The contribution of myeloid cells to tumor pathogenesis has been recognized more than 
100 years ago, but only in the last two decades their role in promoting angiogenesis, cell  
invasion and metastasis has been appreciated and explored in detail. Myeloid cells derive 
from bone marrow precursors of granulocytic linage (Jinushi et al., 2013). They consist of 
various types of cells including monocytes, macrophages, dendritic cells and granulocytes. 
Myeloid cells are the most abundant haematopoietic cells in the body, which protect the 
host from pathogens, eliminate dying cells and mediate tissue remodeling. During tumor 
progression, tumor microenvironment recruits myeloid cells and educates them in support 
to  tumorigenicity.  Recruited  myeloid  cells  are  then  converted  into  potent 
immunosuppressive cells, named myeloid-derived suppressor cells (MDSCs). 
Initially, MDSCs were identified in tumor-bearing mice as cells that co-express Cluster of  
Differentiation  11b  (CD11b)  and  granulocyte  marker  Ly6G/Gr1.  CD11b  mediates 
inflammation by regulating leukocyte adhesion and migration and has been implicated in 
several immune processes such as phagocytosis, cell-mediated cytotoxicity, chemotaksis 
and cellular activation. Expression of Ly6G/Gr1 in bone marrow correlates with granulocyte 
differentiation and maturation. However, the physiological role of Ly6G/Gr1, remains still 
unclear. Today, MDSCs are characterized as monocytic MDSCs or as polymorphonuclear/
granulocytic MDSCs. The murine monocytic lineage has CD11b+Gr1lowLy6ChiLy6G-CD49d+ 
phenotype and the murine polymorphonuclear/granulocytic linage has CD11b+Gr1hiLy6Clow
Ly6G+CD49d- phenotype  (Youn  et  al,  2008).  Monocytic  MDSCs,  and  monocytes/ 
macrophages are functionally and phenotipically very distinct. Monocytic MDSCs, but not 
monocytes, are immunosuppressive and unlike monocytes, express high levels of iNOS 
and  Arginase  1  (ARG1).  Granulocytic  MDSCs  and  neutrophils  are  functionally  and 
phenotipically  very  distinct.  Granulocytic  MDSCs,  but  not  neutrophils,  are 
immunosuppressive. Compared with neutrophils, granulocytic MDSCs are less phagocytic, 
have  increased  reactive  oxygen  species  (ROS)  production  and  express  less  C-X-C 
chemokine receptor 1 (CXCR1) and CXCR2. 
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The  main  function  of  both,  monocytic  and  granulocytic  MDSCs,  is  to  suppress  T-cell 
activation and proliferation. This suppression can be achieved via different mechanisms, 
which can be grouped into four classes.
The first mechanism:
Depletion of nutrients required for lymphocytes
L-arginine  (L-Arg)  is  conditionally  essential  amino-acid  for  adult  mammals,  which  is 
metabolized by arginase I, arginase II and inducible nitric oxide synthase (iNOS). At sights  
of  prominent  infiltration  of  MDSCs,  like  wounds  and  tumors,  L-Arg  is  present  in 
exceedingly low concentration in extracellular matrix. This is a consequence of increased 
consumption of L-Arg by infiltrated MDSCs (Albina et al., 1989). In the enzymatic reaction 
mediated by  arginase 1,  L-Arg is  converted  to  urea and L-ornithine.  In  the enzymatic 
reaction mediated by iNOS, L-Arg degradation generates nitric (II)-oxide (NO). Decreased 
concentration of L-Arg and increased concentrations of urea and NO inhibit T-cell function 
and growth through several different mechanisms:
- decreasing the expression of CD3 zeta chain (CD3ζ), which is a component of
TCR (Rodrigues et al., 2002)
- preventing the expression of cell cycle regulators cyclin D3 and cyclin-dependent 
   kinase 4 (CDK4) (Rodriguez et al., 2007)
- inhibiting Major Histocompatibility Complex (MHC) class II expression on antigen 
   presenting cells (Harari et al., 2004)
- inducing T-cell apoptosis (Rivoltini et al., 2002).
The second mechanism:
Generation of oxidative stress
By the combined and cooperative activities of arginase 1 and iNOS in MDSCs, reactive 
oxygen  species  (ROS),  like  peroxynitrite  and  hydrogen  peroxide,  are  produced. 
Interestingly, increased production of ROS has been detected in tumor-bearing mice and 
in patients suffering from cancer (Kusmartsev et al., 2004; Schmielau et al., 2001). In T-
cells  peroxynitrite induces post-translational  modifications of proteins,  like nitration and 
nitrosilation. Nitration and nitrosilation affect amino-acid residues like cysteine, methionine, 
triptophan and tyrosine (Vickers et al., 1999). Modified proteins loose their function, which 
on the end results in impaired cell signaling and apoptosis of T-cells.
18
Introduction                                                               
The third mechanism:
Interference of lymphocyte trafficking 
Naïve T-cells circulating in the blood express adhesion molecule L-selectin (CD62L) and 
CC chemokine receptor 7 (CCR7). Ligands present on the endothelial cells will bind to L-
selectin  expressed  by  T-cells.  This  interaction  induces  slowing  lymphocyte  trafficking 
through the blood, their rolling and adhesion on endothelium and extravasation through 
high endothelial venules, into secondary lymph organs. Naive T-lymphocytes, which have 
not  yet  encountered  their  specific  antigen,  need  to  enter  secondary  lymph  nodes  to 
encounter their antigen and to be activated. If the expression of L-selectin on the surface 
of T-cells is diminished or lost, T-cells cannot home to lymph nodes and they become 
unresponsive. Interestingly, L-selectin is cleaved from the cell surface by ADAM17. 
Hanson and colleagues demonstrated that the expression of L-selectin on the surface of T-
cells  inversely  correlated with the MDSCs level  in tumor bearing mice (Hanson et  al., 
2009).  Interestingly,  when  they  performed  FACS  staining  for  internal  and  for  surface 
expression of ADAM17 in leukocytes isolated from the blood of tumor bearing mice, they 
were able to show that both, T-cells and MDSCs, internally expressed ADAM17. However, 
only MDSCs, but not T-cells, expressed ADAM17 on the cell surface. They concluded that 
MDSCs express on their plasma membrane ADAM17 that cleaves the ectodomain of L-
selectin.
The fourth mechanism:
Activation and expansion of Treg cell population
Regulatory T-cells (Treg) is a subpopulation of CD4+ T-cells that maintain tolerance to self 
antigens.  The immune system must be able to discriminate between self and non-self. 
When self/non-self discrimination fails, the immune system destroys cells and tissues of 
the body and as a result causes autoimmune diseases. 
In tumors MDSCs promote the clonal expansion of antigen-specific Treg cells and also 
induce the conversion of naïve CD4+ T-cells into induced Treg cells.
In tumor model of colon carcinoma induced with colon cancer cell line MCA26, Huang and 
colleagues provided the evidence that MDSCs can induce development of Treg, in IFN-γ 
and IL-10 dependent mechanism (Huang et al., 2006). Namely, they isolated MDSCs from 
the spleens of tumor bearing mice and co-cultured them with CD4+ splenocytes. They 
detected significant levels of IL-10 and TGF-β, along with IFN-γ in the cell medium of co-
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cultured cells. IL-10 and TGF-β have been shown to induce the development of Treg cells 
(Seo  et  al.,  2001;  Fu  et  al.,  2004),  but  IFN-γ  was  unknown  actor.  Therefore,  they 
hypothesized that MDSCs can produce IL-10 and TGF-β in response to IFN-γ. To test this 
hypothesis, Huang and colleagues isolated MDSCs from mice with large tumor burdens 
and  cultured  them  in  presence  or  absence  of  IFN-γ.  They  demonstrated  that  the 
expression  of  IL-10  was  detectable  in  presence  of  IFN-γ,  but  not  in  IFN-γ  absence. 
Interestingly, MDSCs produced TGF-β in presence or absence of IFN-γ. 
20
Aim of this study                                                           
2 Aim of this study
It has become increasingly clear that inflammation can enhance tumor growth and tumor 
progression.  ADAM17,  as  primary  sheddase  of  transmembrane  protein  TNF-α  and 
sheddase of  adhesion  molecules,  is  required  for  recruitment  of  immune cells  into  the 
tissue  and  is  implicated  in  inflammatory  responses.  It  is  also  shown  that  the 
metalloprotease  ADAM17  is  responsible  for  cleavage  of  growth  factor  receptors  and 
ligands of EGFR, which are necessary for tumor growth and proliferation.
The aim of  present  study was to  investigate the importance of  ADAM17 in the tumor 
stroma for  metastatic  progression  and  spread.  To  address  this,  we used  Lewis  Lung 
Carcinoma (LLC) cells and ADAM17 hypomorphic mice (ADAM17ex/ex mice) in a model of 
experimental metastasis. In an experimental metastasis model, tumor cells are injected via 
the tail  vain.  This injection allows formation of metastatic lesions in the lungs of mice 
without formation of a primary tumor elsewhere in the body. At different time points we 
analyzed  the thickness  of  alveolar  septa,  infiltration  of  immune  cells,  cytokine  and 
chemokine expression to determine the level of lung damage in control and hypomorphic 
mice.
ADAM17ex/ex mice  revealed  significantly  lower  metastasis  than  ADAM17wt/wt  mice  at  all 
followed time points.  We demonstrated  that ADAM17 in  the  host  lung supports  tumor 
growth via inflammatory and proliferatory stimuli. 
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3 Material and Methods
3.1  Material
3.1.1 Solutions and buffers
TAE buffer (50x)     242 g Tris-HCl
57 ml                     Glacial acetic acid (17.4 M)
18.5 g EDTA
to 1000 ml ddH2O
DNA sample buffer 3 ml                         glycerol
1 ml                         0.5 M EDTA pH 8.0
10 mg          Br-phenolblue
10 mg         xylencyanol
to 10 ml ddH2O
(Ca)3(PO4)2 transfection 
reagens 
2 x                         HBS (precipitation buffer)
2 M                         CaCl2
HBS buffer (2x) 8 g NaCl
0.27g Na2HPO4 x 2H2O
12 g HEPES
to 1 l deionized water
Transfection Medium DMEM with Gln and high Glc
10 % FCS
1 mM                        Sodium Pyruvate
20 mM HEPES
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10 ml   Penicillin/Streptomycin
Lysis buffer      150 mM      NaCl
(Cell  and tissue lysis)   2 mM   EDTA
50 mM      Tris-HCl pH 7.4
1% (w/v) Triton X-100
1% (w/v) NP-40
added freshly: 1 mM  Na3VO4
1 mM   NaF
1 mM     PMSF
1x ABTS Tablets
Erytrocyte lysis buffer 8.29 g    NH4Cl 
1 g   KHCO3
0.372 g EDTA-Na
to 1000 ml ddH2O
Leammli buffer (2x)    4 g SDS
10 g 2-mercaptoethanol
20 g glycerol
4 g Br-phenolblue
125 mM Tris-HCl pH 6.8
to 100ml ddH2O
Running gel (10%)    2.5 ml 1.5 mM Tris-HCl pH 8.8
0.1 ml      10% SDS
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0.1 ml     10% APS
3.3 ml   30% acrylamide mix
4 µl TEMED
4 ml       ddH2O
Stacking gel 1.25 ml 1.5 mM Tris-HCl pH 6.8
0.1 ml      10% SDS
0.1 ml 10% APS
1.7 ml  30% acrylamide mix
 Protein Marker                             Page RulerTM Plus (Thermo Scientific)
SDS Running buffer    25 mM Tris-HCl pH 8.3
250 mM  Glycine
0.1%   SDS
                         
Transfer buffer     25 mM    Tris-HCl pH 8.3
192 mM  Glycine
20 % Methanol
                      
NETG - Blocking  and 150 mM      NaCl
Washing buffer   5 mM   EDTA
50 mM Tris-HCl pH 7.5
0.04%   gelatine
0.02%     Tween 20
Stripping buffer  15g Glycine pH 2.2
0.1g   SDS
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10ml     Tween 20   
Cell culture medium DMEM high glucose
10% FCS
10ml Penicilin/Streptavidin
Flushing medium MEM high glucose (Glutamax)
1 x non-essential amino acids
1 mM Sodium Pyruvate
50 µM β-mercaptoethanol
BMN medium MEM high glucose (Glutamax)
20 % FCS
1 x non-essential amino acids
1mM Sodium Pyruvate
50 µM β-mercaptoethanol
Complete medium  DMEM (Glutamax)
10% FCS
10 ml Penicilin/Streptavidin
50 µM beta-mercaptoethanol
ADAM10 inhibitor 3 µM GI254023X
ADAM17 and ADAM10 
inhibitor 3 µM GW280264X
Bouin's solution 5% acetic acid
9% formaldehyde
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0.9% Picric acid
PBS (1x) 137 mM   NaCl
 2.5 mM KCl
 8.1 mM Na2HPO4
 1.5 mM  KH2PO4  pH 7.2-7.4
Washing buffer  0.05%   Tween-20 in PBS pH 7.2-7.4
Blocking buffer/Reagent       1%    BSA in PBS pH 7.2-7.4
Diluent 
Streptavidin-HRP 1:200      Solution in Blocking buffer
Stop Solution    1.5 M   H2SO4
FACS Blocking solution 50 µl  PBS
per sample 2.5 µl FCS
5 µl FC Block
FACS buffer  per sample 50 µl PBS
2% FCS
                                                                         
3.1.2  Primers
All primers were purchased at Sigma.
Primer 
name
Primer sequence Product 
size (bp)
Tm 
(oC)
Number of 
cycles
Elongation 
time (s)
3' flox_ADAM17 
(genotyp.)
5'-CTTATTATTCTCGTGGTCACC-3' 250/500 52 40 60
5' flox_ADAM17 
(genotyp.)
5'-TATGTGATAGGTGTAATG-3'
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beta actin up 5'-GTGGGGCGCCCCAGGCACCA-3' 500 55 27 30
beta actin down 5'-CTCCTTAATGTCACGCACGATTTC-3'
HES1_fw 5'-AAGCACCTCCGGAACCTGCAGC-3' 609 64 30 33
HES1_rev 5'-AGTGGCCTGAGGCTCTCAGTTCC-3'
DLL1_fw 5'-CCTCGTTCGAGACCTCAAGGGAG-3' 550 65 30 30
DLL1_rev 5'-TAGACGTGTGGGCAGTGCGTGC-3'
IL-6_fw 5'-TCTCTGCAAGAGACTTCCATCCAGT-3' 71 64 31 5
IL-6_rev 5'-AGTAGGGAAGGCCGTGGTTGTCA-3'
TNF-alpha_fw 5'-AGCCCACGTCGTAGCAAACCAC-3' 411 64 28 25
TNF-alpha_rev 5'-TAGACCTGCCGGACTCCGC-3'
ICAM-1_fw 5'-GATCCCTGGGCCTGGTGATGCT-3' 740 66 28 45
ICAM-1_rev 5'-TGTGCTCTCCTGGGTCGGCA-3'
TGF-alpha_fw 5'-GCTACTCGCCAACCGCAGGG-3' 430 65 30 28
TGF-alpha_rev 5'-GCGGAGCTGACAGCAGTGGAT-3'
AR_fw 5'-TCACAGTGCACCTTTGGAAACGAT-3' 153 64 30 10
AR_rev 5'-TCCGGTGTGGCTTGGCAATGA-3'
MMP-9_fw 5'-TGGGCAAAGGCGTCGTGATCC-3' 893 66 29 54
MMP-9_rev 5'-AGGTGAGGGGGCGCCTGTAG-3'
IL-1beta_fw 5'-ACGGACCCCAAAAGATGAAGGGCT-3' 523 66 28 31
IL-1beta_rev 5'-TCCAGCTGCAGGGTGGGTGT-3'
PCNA_fw 5'-GCGTGAACCTCACCAGCATGTCC-3' 640 65 29 34
PCNA_rev 5'-CACGCTGGCATCTCAGGAGCA-3'
cxcl2_fw 5'-CAGGGGCTGTTGTGGCCAGTG-3' 250 66 30 15
cxcl2_rev 5'-CCCAGGCTCCTCCTTTCCAGGT-3'
ccl4_fw 5'-TCGTGGCTGCCTTCTGTGCTC-3' 280 65 29 16
ccl4_rev 5'-CTGAAGTGGCTCCTCCTGCCC-3'
cxcl12_fw 5'-GCTCTGCATCAGTCACGGTAAACCA-
3'
296 65 31 18
cxcl12_rev 5'-TGCCCTTGCATCTCCCACGGA-3'
cx3cl1_fw 5'-GCCTGGCCGCGTTCTTCCAT-3' 170 66 31 11
cx3cl1_rev 5'-CGTCTCCAGGACAATGGCACGC-3'
IL-10_fw 5'-GAGGCGCTGTCATCGATTTCT-3' 724 60 28 44
IL-10_rev 5'-GTTTTCAGGGATGAAGCGGC-3'
EGF_fw 5'-CTGTTGTTGGAGGGAGCGAT-3' 330 60 28 20
EGF_rev 5'-GGGTGACCTACGTCGTTCTG-3'
HGF_fw 5'-TCGGATAGGAGCCACAAGGA-3' 370 60 29 22
HGF_rev 5'-CGAAGGCCTTGCAAGTGAAC-3'
VEGFR_tr1_fw 5'-CCATCTGGGCCAAAGATACC-3' 173 59 30 12
VEGFR_tr1_rev 5'-CTGGGTGTGAGAGGTTCCAC-3'
VEGFR_tr2_fw 5'-AGCTGAGAAAGACTGCAAGGC-3' 547 60 30 31
VEGFR_tr2_rev 5'-GGCCCAGAGGATTTGGAAGAA-3'
cherry_fw 5'-GCTGTCCTTCCCCGAGGGCT-3' 270 66 32 15
cherry_rev 5'-TCGTAGTGGCCGCCGTCCTT-3'
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lego_17sh_fw 5'-
TGGTTAGTACCGGGCCCGCTCTAGAGA
GGGCCTATTTCCCATGATTCCTTC-3'
360 72 30 1200
lego_17sh_rev 5'-
AGCTTATCGATACCGTCGACGTCGACG
AATTCAAAAACCCTTGAAGAATAC-3'
3.1.3 Primary Antibodies
anti-β actin (8H10D10)                  rabbit polyclonal antibody which detects endogenously         
                                                       expressed human β-actin (45kDa) with species     
                                                       crossreactivity to mouse (Cell Signaling, Boston, USA); WB 
                                                       dilution: 1:1000 in NETG buffer    
                                                                                 
anti-STAT3 (124H6)                       mouse monoclonal antibody which detects endogenously   
                                                       expressed human STAT3 (79, 86kDa)  with species     
                                                       crossreactivity to mouse (Cell Signaling, Boston, USA); WB 
                                                       dilution: 1:1000 in NETG buffer 
anti-P-STAT3 (D3A7)                    mouse monoclonal antibody which detects endogenously   
                                                      expressed human STAT3 (79, 86kDa) only when 
                                                      phosphorylated at tyrosine 705  with species crossreactivity 
                                                      to mouse (Cell Signaling, Boston, USA); WB  dilution:
                                                     1:1000  in  NETG buffer        
  
anti-ERK1/2 (L34F12)                mouse monoclonal antibody which detects endogenously   
                                                      expressed human ERK (42, 44kDa)  with species     
                                                      cross-reactivity to mouse (Cell Signaling, Boston, USA); WB 
                                                      dilution: 1:1000 in NETG buffer   
anti-P-ERK1/2 (D1H6G)            mouse monoclonal antibody which detects endogenously   
                                                     expressed human p44 and p42 MAPK Kinase (Erk1 and
                                                     Erk2) when dually phosphorylated at Thr202 and Tyr204 of 
                                                     Erk1 and Thr185 and Tyr187 of Erk2 and singly 
                                                     phosphorylated at Thr202 at Erk1, with species
                                                     crossreactivity to mouse (Cell Signaling, Boston, USA); WB 
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                                                     dilution: 1:1000 in NETG buffer      
                                                    
anti-I-kappaB (L35A5)                mouse monoclonal antibody which detects endogenously 
                                                     expressed human IkappaBα (39kDa)  with species     
                                                     crossreactivity to mouse (Cell Signaling, Boston, USA); WB  
                                                     dilution: 1:1000 in NETG buffer    
   
anti-P-IKK (16A6)                         rabbit monoclonal antibody which detects endogenously   
                                                     expressed human P-IKKa/b only when IKKa phosphorylated  
                                                     at Ser176/180 and IKKb phosphorylated at Ser177/181 
                                                     (85, 87kDa) with species crossreactivity to mouse (Cell 
                                                     Signaling, Boston, USA); WB dilution: 1:1000 in NETG buffer 
anti-ADAM17                              rabbit polyclonal antibody 10.1 which recognizes the catalytic  
                                                    domain was used; kindly provided by Dr Athena Chalaris
                                                           
Secondary antibodies
Secondary  antibodies  were  horseradish-peroxydase  (HRP)-conjugated  and  used  in 
dilution 1:5000 in NETG buffer. They were purchased from Pierce (Rockford, USA).
3.1.4 Recombinant proteins
rm G-CSF                                  recombinant murine Granulocyte Colony Stimulating  
                                                   Factor used in experiments was produced in E.coli
                                                   (Immuno Tools) as a single non-glycosylated polypeptide
                                                   chain with 179 amino acids and molecular mass of 19kDa 
  
rm M-CSF                                  recombinant murine Macrophage Colony Stimulating
                                                   Factor used in experiments was produced in E.coli
                                                  (ImmunoTools) as a disulfide homodimer, non-glycosylated  
                                                   polypeptide chain  with 2 x 156 amino acids and molecular  
                                                   mass of 36.4 kDa
rm TNF-α                                  recombinant murine Tumor Necrosis Factor alpha used in 
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                                                  experiments was produced in E.coli (ImmunoTools) as a
                                                  solubile 156 amino acid protein (17.3 kDa) which
                                                  corresponds to C-terminal extracellular domain of the full 
                                                  lenght transmembrane protein
                        
3.1.5 ELISA (Enzyme Linked Immunosorbent Assay)                                                
TNF-α  (DY410)  and  IL-6  (DY406)  ELISA  kits  were  purchased  from  R&D  Systems 
(Wiesbaden-Nordenstadt, Germany). MCP-1/ccl2 (88-7391) ELISA kit was purchased from 
eBiosciences  (San  Diego,  USA).  ELISA microtiter  plates  were  purchased  at  Thermo 
Scientific, USA.
3.1.6 FACS antibodies
Fc Block                                            rat anti-mouse CD16/CD32 (BD Pharmingen)   
IgG2b k Isotype Control FITC           rat IgG2b, k monoclonal antibody is used as an    
                                                          isotype control immunoglobulin (BD Pharmingen)
anti-Ly6G/Gr1                                    FITC labeled rat anti-mouse Gr1 antibody reacts  
                                                          with mouse Ly6G, a 21-25 kDa protein (eBioscience);  
                                                          FACS dilution 1:100  
anti-Ly6G/Gr1                                    Pe-Cy7 labeled rat ani-mouse Gr1 monoclonal  
                                                          antibody (RB6-8C5) reacts with mouse Ly-6G; a 21- 
                                                          25 kDa  protein (eBioscience); FACS dilution 1:100 
  
F4/80                                                  APC labeled rat anti-mouse F4/80 antibody reacts  
                                                           with mouse F4/80, a 160 kDa glycoprotein  
                                                           (BioLegend) ; FACS dilution 1:100  
                                                    
CD11b                                               FITC labeled rat anti-mouse M1/70 monoclonal  
                                                          antibody reacts with mouse CD11b, a 165-170 kDa  
                                                          integrin alpha M (eBioscience); FACS dilution 1:100
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CD11c                                                FITC labeled rat anti-mouse CD11c (N418)  
                                                           monoclonal antibody reacts with mouse CD11c, the  
                                                          integrin alpha x (eBioscience); FACS dilution 1:100 
anti-TNF-α                                         goat anti-mouse TNF-α monoclonal antibody (Capture  
                                                          antibody from TNF- α ELISA kit, R&D Systems) was  
                                                          used as a primary antibody (dilution 1:100); as the  
                                                          secondary antibody APC labeled anti-goat antibody  
                                                          was used (dilution 1:100) 
                                                         
anti-ADAM17                                     rat anti-mouse ADAM17 antibody against catalitic  
                                                          domain of  ADAM17 was used as a primary antibody;  
                                                          anti-goat APC labeled antibody was used as the  
                                                          secondary antibody, both kindly provided by Dr  
                                                          Ahmad Trad; FACS dilution 1:200
                                                         
3.1.7 Immunohistology                                                        
HE staining                                       Gill3 Hematoxylin (Thermo Scientific, Cheshire, United 
                                                            Kingdom) and Giemsa’s azur eosin methylene blue  
                                                            solution (Merck, Darmstadt, Germany) were used  
                                                            according to manufacture’s instruction
anti-Ly6B.2/G1                                 rat anti-mouse Gr1 monoclonal antibody  
                                                         recognizes Ly-6B.2, a polymorphic 40 kDa antigen 
                                                         expressed by polymorphonuclear cells, but absent on
                                                         resident tissue macrophages (AbDserotec, 
                                                         Duesseldorf, Germany);  dilution 1:200 
  
anti-F4/80                                         rat anti-mouse F4/80 monoclonal antibody recognizes
                                                         Kupffer  cells, Langerhans cells, peritoneal
                                                         macrophages, and splenic red pulp macrophages 
                                                        (Caltag); dilution 1:50  
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anti-PCNA                                       rat anti mouse PCNA monoclonal antibody recognizes
                                                        PCNA p36 protein expressed in proliferating cells 
                                                        (Santa Cruz Biotechnology, Texas, USA); dilution 1:100
3.1.8 Proteome Profiler Antibody Array
For simultaneous profiling of relative levels of multiple cytokines from tissue lysates, the 
Mouse  Cytokine  Array  Panel  A  (R&D  Systems,  Minneapolis,  USA)  was  used.  For 
simultaneous detection of the relative Receptor Tyrosine Kinase (RTK) phosphorylation in 
tissue lysates, the Mouse RTK Kit (R&D Systems, Minneapolis, USA) was used.
3.2 Methods
3.2.1  RNA Isolation
Total RNA from lung tissue was isolated using the NucleoSpin RNA II Kit (Macherey-Nagel 
GmbH,  Dueren,  Germany)  according  to  the  manufacturer's  instructions.  RNA 
concentration was determined using NanoDrop ND-1000 (peqLab Biotechnologie GmbH, 
Germany). For semiquantitative RT-PCR reaction 150 ng of RNA was used for the reverse 
transcription. For real time RT-PCR reaction 500 ng of RNA was used for the reversed 
transcription.  The  first  strand  cDNA  synthesis  was  performed  according  to  the 
manufacturer's instructions (Fisher Scientific GmbH, Schwerte, Germany): 
Template RNA total RNA  150ng-500ng
Primer oligo(dT) 0.5 µg (100pmol)
Master Mix ddH2O To 13 µl
5X reaction buffer 4µl
dNTP  Mix,  10mM 
each
2µl
Revert  Aid 
Transcriptase
1µl
Total volume 20µl
All  components  were  kept  on ice.  Each sample  was mixed with  the  Master  Mix,  and 
incubated at 37oC for 10 min. After this time samples were heated at 60oC for 1 h and the 
reaction was terminated by heating at 70oC for 10 min. 
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For semi-quantitative RT-PCR reaction, the following protocol was used:
cDNA 2 µl
Forward primer (10μM) 0.9 µl
Reverse primer (10μM) 0.9 µl
dNTP (10mM) 0.6 µl
Dream taq polymerase (1U/µl) 0.6 µl
Dream Taq Buffer (10x) 3 µl
ddH2O 22 µl
Total volume 30 µl
3.2.2 shADAM17_pLeGO_C/BSD vector vector
The  expression  plasmid  shADAM17-pLKO.1  containing  a  validated  murine  ADAM17 
targeted shRNA under the control of the human U6 promotor, was obtained from Sigma. 
The  shRNA  cassette  including  the  hU6  promotor  was  PCR  amplified  with  primers 
introducing a 5' Xba I site and 3' Sal I site.
ddH2O 34.5 µl
5 x HF buffer 10 µl
shADAM17pLKO.1 (50 ng) 1 µl
dNTP (10mM) 1 µl
lego_17sh_fw 1.5 µl
lego_17sh_rv 1.5 µl
Phusion Hot Start II Polymerase 0.5 µl
98oC          30 min
98oC          10 min
72oC          20 min     30 cycles
72oC            5 min
4oC                infin.
The resulting PCR product was purified from an agarose gel and Xba I/Sal I digested. 
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To remove the murine U6 promoter, the vector pLeGO-C/BSD was Xba I/Xho I digested 
according to the following protocol:
ddH2O 20 µl
10 x Tango buffer 6 µl
pLEGO-C/BSD (2 µg) 2 µl
Xba I 1 µl
Xho I 1 µl
Total volume 30 µl
PCR  amplific.  product  extracted 
from the gel
46 µl
10 x Tango buffer 12 µl
Xba I 1 µl
Sal I 1 µl
Total volume 60 µl
The digestion products were separated on an agarose gel and the digested vector was 
purified by gel extraction. Digested PCR product and vector were subsequently ligated.
pLEGO-C/BSD 2.5 µl
PCR  amplific.  product  extracted 
from the gel
1 µl
10 x T4 DNA Ligase buffer 2 µl
ddH2O 23.5 µl
T4 DNA Ligase 1 µl
Total volume 30 µl
The final product was termed sh17-pLeGO-C/BSD and verified by sequencing.
3.2.3  Generation of LLC cells with stable ADAM17 knock down
For generation of lentiviral particles following vectors were used:
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Vectors 10 µg/ 10 cm dish PMDLg/pRRE plasmid
5 µg/ 10 cm dish pRSV-Rev plasmid
2 µg/ 10 cm dish phCMV-VSV-G 
15 µg/ 10 cm dish Adam17 pLKO.1-puro
15 µg/ 10 cm dish LeGO-C/BSD
15 µg/ 10 cm dish Sh17-pLeGO-C/BSD
    1)Generation of lentiviral particles
Day 1:
In the afternoon 5 x 106 HEK293T cells were seeded into a 10 cm dish
Day 2:
All the reagents and plasmids were thawed at the room temperature.
Indicated amount of plasmids was diluted in water (437.5 µl) and it was added 62.5 µl of 2 
M CaCl2 solution. The 15ml falcon tube was filled with 500 µl of 2 x HBS and DNA/CaCl2 
solution  was  added  drop  wise  while  blowing  air  through  the  solution  using  a  pasteur 
pipette. This mixture was incubated for 10 – 20 min at room temperature. The medium 
from  the  cells  was  replaced  with  fresh  medium,  containing  25  µM  Chloroquine. 
Subsequently DNA mixture was added, drop wise, to the cells with gentle swirling . Cells 
were incubated for 6 – 12h at 37oC, 5% CO2 and 95% humidity.
Medium was changed 8h later to 8 ml. From this moment on, medium was harvested 
every 12h.
Day 3:
Early
The supernatant (supernatant 1) was harvested and filtered through 0.45 µm or 0.22 µm 
filter into 2 ml tubes. For the second collection, 8 ml of fresh medium was added to the  
supernatant of cells. Virus containing supernatant (supernatant 1) was quickly frozen at 
-80oC.
Late
The supernatant (supernatant 2) was harvested in the same way as supernatant 1 and the 
new 8 ml of fresh medium was added. Successful HEK293T transfection was verified by 
fluorescent microscopy.
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Day 4
Early
The supernatant 3 was harvested, as described above in Day3.
Late
The supernatant 4 was harvested, as described above in Day3.
  
    2) Titration of Lentiviral particles
The titration of Lentiviral particles was performed in the following way:
Day 1 
HEK293T cells, 50 000 cells per well, were seeded in a 24 well plate in a total volme of  
500  µl.  Cells  were  left  2  –  5h  to  attach  and  then  polybrene  was  added  to  a  final 
concentration of 8 µg/ml. Different volumes of viral particles ( 0.1 µl, 1 µl, 10 µl and 100 µl)  
were added in triplicates to the wells. The plate was centrifuged for 1h at 1000g and 24oC.
Day 2
The medium was changed (1 ml per well) to medium without polybrene.
Day 4
Cells were analysed in a BD FACS CantoTM (BD, Heildelberg, Germany) flow cytometer.  
The titer was calculated from the wells showing  5 – 20% of positive cells. 
Titer was calculated according to the formula:
T = N*P/V        T – titer
                        N – number of plated cells
                        V – volume of added supernatants
                        P – proportion of transduced cells
The  supernatants  with  the  best  titer  were  used  for  the  transduction  of  the  LLC  cells  
according to the protocol described above.
After transduction of LLC cells, 10 cells per ml were seeded in a 96 well plate and positive  
clones  were  identified  using  the  fluorescent  microscope.  After  clone  expansion,  the 
expression of ADAM17 was analysed using Western Blot Analysis, and semi-quantitative 
RT-PCR analysis.
3.2.4 Cell culture and cell lines
The murine cell lines LLC (Lewis Lung Carcinoma) and B16F1 (melanoma cell line), both 
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derived  from  C57Bl/6N  mice,  were  purchased  from  CLS  (Eppelheim,  Germany).  The 
human HEK293T cell line was purchased from DSMZ (Braunschweig, Germany). 
All  cell  lines were cultured in the cell  culture medium (see the section 3.1.1) at  37 oC, 
5%CO2  and 95% humidity. At the confluency of 70%-80%, cells were detached from the 
tissue flask using trypsin/EDTA and splited in a ratio 1:5. 
For mice injection LLC and B16F1 cells were prepared according to the following protocol:
1) Cells were detached from the tissue flask and centrifuged at 1200-2000 rpm for 7 
min
2) The cell pellet was resuspended in ice cold 1 x PBS (see the section 3.1.1) and 
cells were adjusted to a final concentration of  5 x 105 cells per ml 
3) 1ml of  resuspended cells  was pipeted into  each eppendorf  tube,  centrifuged at 
1200-2000 rpm for 7 min and the cell pellet was resuspended in 250μl ice cold 1 x 
PBS for mice injection.
3.2.5 Proliferation assay
Cells were counted and seeded into six well plates to a final concentration of 5 x 10 5 cells 
per well. Cells were incubated for 4 – 6h  at 37oC, 5% CO2 and 95% humidity in cell culture 
medium (see the section 3.1.1). Subsequently, medium was changed to DMEM without 
FCS and cells were starved over night. The following day, cell were stimulated with rm 
TNF-α (see the section 3.1.4) in the final concentrations of 0.01 ng/ml, 0.03 ng/ml, 0.1 
ng/ml and 0.3 ng/ml. Cells were counted 24h, 48h, 72h and 144h post stimulation.
3.2.6  Protein extraction from tissues and cultured cells
The same lysis buffer was used for the cell and tissue lysis (see the section 3.1.1). For the  
cell  lysis 500μl of a lysis buffer per 5 x 105 cells was used. Cells were scraped from the 
plate  with  the  cell  scraper,  and  subsequently  transferred  into  eppendorf  tubes  and 
resuspended by pipetting. Lysates were cleared by centrifugation at 13,000 rpm for 10 min 
at 4oC. 30 μl of lysate was mixed with 5x Leammli , boiled at 95oC for 10 min and used for 
the SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently Western Blot 
analysis (see the following section).
For tissue lysis 750 μl of lysis buffer per 40 mg of tissue sample was used. Tissue was 
lysed  for 2 min at 5000 rpm using the Precellys homogenizer (PEQLAB Biotechnologie 
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GMBH, Erlangen, Germany). Lysate was centrifuged on 13,000 rpm for 10 min at 4oC. 
After centrifugation, protein concentration was determined from the supernatant using the 
BCA Protein Assay Kit according to manufacture's instructions (PierceTM , Rockford, USA) 
and 200  μg of protein lysate was used for the SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and subsequently Western Blot analysis (see the sections 3.2.7 and 3.2.8).
3.2.7 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins  were separated on a polyacrylamide gel,  according  to  ther  molecular  weight, 
using the Mini-Protein III system (BioRad). The gels were run for 90 min at 120 V const. 
3.2.8 Immunoblotting Analysis
After  the proteins were  separated by SDS-PAGE,  they were transferred onto a PVDF 
membrane  (GE  Healthcare,  Uppsala,  Sweden)  using  MINI  TRANSBLOT  apparatus 
(BioRad Laboratories GmbH, München, Germany). After the protein transfer for 90 min at 
100V const, the PVDF membranes were placed into a plastic container in NETG buffer 
(see  the  section  3.1.1)  and  blocked  for  1h  at  room  temperature.  Subsequently,  
membranes were incubated with primary antibody for 1h at room temperature or over night  
at 4oC. The excess of the primary antibody was removed by washing the membrane in 
NETG buffer 3 times for 10 min, after which the membrane was incubated  for 1 h with the 
secondary antibody followed by 3 times washing in NETG. ECL-Plus Western blotting 
Detection Kit  (Piers, Massachusetts, USA) was used for the protein detection with the 
CCD camera system LAS-1000 (Fujifilm, USA).
3.2.9 Generation of  Bone Marrow Derived Neutrophils (BMDNs)
7-11  weeks  old  mice  were  killed  via  cervical  dislocation,  and  femora  and  tibia  were 
dissected.  The  ends  of  the  bones  were  removed  and  the  bone  marrow  was  flushed 
through a 70 μm cell  mesh with  the flushing medium (see the section 3.1.1)  into the 
collection tube. The pellet from the collection tube was resuspended in BMN medium (see 
the section 3.1.1) to a final concentration of 1x106 cells per ml. rm G-CSF (see the section 
3.1.4) was added to a final concentration of 5 ng/ml. Finally, the cells were seeded into the 
24-well plate with 1ml per well.
After 4-5 days additional 500μl of fresh BMN medium was added. Cells were differentiated 
after 9 days. To ascertain the purity of differentiated cells after 9 days, extracellular FACS 
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staining was performed using anti-CD11b and anti-Gr-1 antibodies.
3.2.10 Generation of Bone Marrow Derived Macrophages (BMDMs)
7-11 weeks old  mice were killed via  cervical  dislocation, femura and tibia  bones were 
dissected, the ends of the bones were removed and the bone marrow was flushed with 
5ml of ice cold 1 x PBS (see the section 3.1.1) into a 50 ml falcon tube. Cell suspension  
was passed through a 70 μm cell strainer and subsequently centrifuged at 300 x g for 10 
min at  40C. Supernatant  was discarded.  The pellet  was resuspended in 5 ml  ice cold 
erythrocyte lysis buffer and incubated for 5 min at 40C. After incubation, 45 ml of PBS was 
added and centrifuged as above. Cell pellet was resuspended into the complete medium 
(see the section 3.1.1) supplemented with rm M-CSF in final concentration of 50 ng/ml,  
and cell density was adjusted to 7.5 x 105  cells per ml. Cells were seeded into 10 cm 
bacteria dishes, for less adherence, and cultured for 3 days. After 3 days, 5 ml of complete 
medium was added. After 5-6 days macrophages were differentiated and ready to use. To 
detach macrophages from the plate, 1-2 ml of 1% EDTA in 1 x PBS was used and the  
plates were placed at 370C in the incubator for 25 min. After 25 min detached cells were 
resuspended into 10 ml of ice cold 1 x PBS and centrifuged at 300 x g for 10 min at 4 0C. 
Cell were resuspended in the complete medium (see the section 3.1.1) and plated for the 
experiment.
3.2.11 Enzyme Linked Immunosorbent Assay (ELISA)
To determine the  precise  concentration  of  the  protein  of  interest  from the  cell  culture 
supernatants or of the tissue homogenates, the sandwich ELISA was used. The ELISA 
microtiter plate was coated with 100μl of Capture Antibody diluted in PBS according to the 
manufacture's protocol. Plate was sealed and incubated overnight at room temperature. 
The following day, the excess of the Capture Antibody was removed by washing 3-5 times 
in the Washing buffer (section 3.1.1) with complete removal of liquid at each step. The 
plate was blocked with the 300μl Reagent Diluent for 1h at room temperature. Plates were 
washed 3-5 times with Washing buffer to remove the excess of Capture antibody. After 
aspiration, 100μl of sample or Standard, diluted in the Reagent Diluent according to the 
manufacture’s recommendation, was added to the wells (each sample was measured in 
the  duplicate  or  triplicate)  and  incubated  for  2h  at  the  room  temperature.  The 
aspiration/wash step was repeated. Detection Antibody was diluted in Reagent Diluent 
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according to the manufacture's protocol and 100μl was added to each well and incubated 
for 2h at the room temperature. Streptavidin conjugated to horseradish-peroxidase and 
peroxidase  substrate  (Roche,  Mannheim,  Germany)  were  used  for  the  subsequent 
detection in the colorimetric reaction. Absorption was measured at 475nm in an ELISA 
plate reader TECAN RainBow (Tecan GmbH, Carlsheim, Germany).
3.2.12 Animal breedings
Hypomorphic male C57Bl/6N ADAM17ex/ex mice (Chalaris 2010), ADAM17wt/wt littermates, 
sgp130Fc transgenic mice and C57Bl/6N (Charles River, Sulzfeld, Germany) male mice 
were used in this study. ADAM17ex/ex mice were backcrossed to the C57Bl/6N background 
9 times. sgp130 mice were backcrossed to the C57Bl/6N background 8 times. Mice were 
maintained at a 12 hour light-dark cycle under standard conditions, provided with food and 
water ad libitum.
3.2.13 Model of experimental metastasis
For all animal experiments male mice 9-12 weeks of age were used. All experiments were 
performed according to the German guidelines for animal care and protection.
Hypomorphic ADAM17ex/ex mice and ADAM17wt/wt littermates, sgp130 and C57Bl/6N mice 
were  injected  through  the  tail  vain  with  LLC  or  B16F1  cells,  prepared  as  previously 
described (see the section 3.2.4). Mice were sacrificed via cervical dislocation at 20h, 7, 
14 and 21 days post injection, organs were excised and frozen in liquid nitrogen for further 
analysis. 
3.2.14  FACS analysis of tumor bearing lung tissue
The lungs were excised, cut in pieces and digested in 5 ml of 0.1% Collagenase Type IV 
(Serva, Electrophoresis GmbH, Heidelberg, Germany) diluted in PBS at room temperature 
for 2h. A single cell  suspension was generated by sucking through a 26G needle and 
passing through 70 μm cell strainer (BD Falcon, Germany). Cells were centrifuged for 8 
min at 400 g at 4oC, the pellet was resuspended in 5 ml of erythrocyte lysis buffer (see the 
section 3.1.1) and incubated at 37oC for 5 min. Cell lysis was stopped by adding a 10 fold 
volume  of  ice  cold  1  X  PBS.  After  sedimentation  for  8  min  at  400  g,  cells  were 
resuspended in the FACS buffer, stained and analysed with Flow Cytometer BD FACS 
CantoTM (BD, Heidelberg, Germany).
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3.2.15 Immunohistochemistry
Tissue samples  were  incubated in  4% formaldehyde  over  night  at  40C. The next  day 
samples were washed and kept in water for 3-5 hours at room temperature. After washing, 
they were incubated in 50% ethanol over night, and then it was proceeded with the alcohol 
dehydration series according to the protocol:
1 70% ethanol 60 min
2 96% ethanol I 30 min
4 100% ethanol I 60 min
5 100% ethanol II 30 min
6 Xylol I 120 min
7 Xylol II 120 min
8 Paraffin I 30 min
9 Paraffin II 60 min or over night
10 Paraffin III 60 min
After paraffin embedding, sections were cut to 5 μm thickness and stained according to the 
following protocols:
HE  staining -  Tissue  sections  were  incubated  for  10  min  in  Gill3  Hematoxylin, 
differentiated in 0.5% acetic acid, rinsed in tap water and counterstained with Giemsa's 
azur eosin methylene blue solution.
Neutrophil  and  Macrophage  stainings -  Tissue  sections  were  deparaffined  and 
rehydrated according to the protocol:
1 Xylol 3 x 5 min
2 100% Ethanol 2 x 5 min
3 95% Ethanol 2 x 5 min
4 70% Ethanol 1 x 5 min
5 ddH2O by choice
After  rehydratation,  peroxidase  was blocked with  H2O2 for  10  min,  and  sections  were 
washed several times first in distilled water and then in PBS. Sections were demasked 
with  proteinase K (1µl/1ml) digestion for 5 min, and subsequently washed with distilled 
water and PBS. 
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Antibodies (see the section 3.1.7) were diluted in the Sample Diluent (Dako, Glostrup, 
Denmark) with 1:100 or 1:200 dilution for anti-Gr1 and 1:50 for anti-F4/80 over night at 
4oC.  After  incubation  with  biotinylated  polyclonal  rabbit  anti-rat  antibody  (Dako, 
Glostrup,Denmark)  and  EnVision-HRP  (Dako,  Glostrup,  Denmark),  the  signal  was 
developed with AEC Substrate (Dako, Glostrup, Denmark). Samples were counterstained 
with Shandon Gill3 Hematoxylin.
PCNA  staining - Cut sections were treated the same way as described in the section 
3.2.15 to the step of staining with the primary antibody. Antibody was diluted in the Sample 
Diluent (Dako, Glostrup, Denmark) with 1:100 dilution over night at  40C. After incubation 
with  biotinylated  polyclonal  rabbit  anti-rat  antibody  (Dako,  Glostrup,  Denmark)  and 
EnVision-HRP (Dako, Glostrup, Denmark), the signal was developed with AEC Substrate 
(Dako,  Glostrup,  Denmark).  Samples  were  counterstained  with  Shandon  Gill3 
Hematoxylin.
3.2.16 Proteome ProfilerTM – Mouse Cytokine Array
To determine the relative expression levels of multiple cytokines from tissue homogenates, 
Mouse Cytokine Array Panel A was used (see the section 3.1.8). Capture Antibodies for 
different  cytokines  were  spotted  in  duplicate  on  nitrocellulose  membranes.  200μg of 
sample was diluted and mixed with the cocktail of biotinylated detection antibodies. The 
sample/antibody mixture was then incubated with the Mouse Cytokine Array membranes 
over night at 4oC. To remove the excess of unbound material, membranes were washed in 
the Washing solution (provided by manufacturer), incubated with the Streptavidin-HRP and 
chemiluminescent detection reagents. The signal was detected with the CCD camera Fuji 
LAS1000. The quantification was determined with the program ImageJ version 1.47.
3.2.17 Proteome ProfilerTM – Mouse Phospho-RTK Array
Proteome Profiler Phospho-RTK antibody Array (RTK Array) is a tool which enables to 
detect changes in phosphorylation of receptor tyrosine kinases between different samples. 
Capture antibodies  for  different  phosphorylated receptors were spotted in duplicate on 
nitrocellulose membranes. Recombinant tyrosine phosphorylated proteins were used to 
choose  capture  antibodies.  200μg of  lung  tissue  lysate was  diluted  and  prepared 
according to manufacture's recommendation, and incubated with the RTK Array 
42
Material and Methods                                                           
membranes over night at  4oC.To remove the excess of unbound material,  membranes 
were  washed  in  the  Washing  solution  (provided  by  manufacturer),  incubated with  the 
Streptavidin-HRP and chemiluminescent detection reagents. The signal was detected with 
the  CCD camera  Fuji  LAS1000.  The  quantification  was  determined  with  the  program 
ImageJ version 1.47.
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4 Results
4.1 ADAM17ex/ex mice are protected in a model of experimental metastasis
In order to study the role of ADAM17 in the metastatic niche, we used a murine metastasis 
model. Hereby, syngeneic tumor cells were injected i.v. into the tail vein of wild type or 
ADAM17ex/ex mice. Animals were sacrificed at different time points post injection at 20h, 7, 
14 and 21 days (Figure 4.1.1).
Figure 4.1.1 Metastasis to the lungs and liver after LLC inoculation.  a Lungs of ADAM17wt/wt and 
ADAM17ex/ex mice 7,  14 and 21 days after inoculation with 5x105 LLC cells per mouse (tumors are 
indicated by black arrows; for the ease of detection, lungs were stained with Bouin's solution (right 
panel, 21 days, lungs colored in yellow),  b Liver of ADAM17wt/wt  mice 21 days after LLC inoculation 
(tumors are marked by black arrows),  c Number of surface tumors in the lungs and d lung weight of 
ADAM17wt/wt and ADAM17ex/ex mice 21 days after LLC inoculation. Data are represented as means  ± 
s.e.m.  * p<0.05.
We were not able to detect any macroscopic differences in the lungs between ADAM17wt/wt 
and ADAM17ex/ex mice as early as 20h and 7 days post LLC injection. First macroscopic 
differences  appeared  14 days  after  tumor  cells  injection  (Figure  4.1.1  a).  ADAM17wt/wt 
animals had several small visible tumors, while the lungs of  ADAM17ex/ex  animals revealed 
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normal  lung  morphology.  21  days  after  LLC  inoculation,  we  detected  a  significant 
difference in the number of microscopical tumors in the lungs (Figure 4.1.1 c). Wild type  
mice developed five times more tumor lesions in the lungs than ADAM17ex/ex mice. This 
was also reflected in a significant difference in total lung weight (Figure 4.1.1 d). While 
ADAM17ex/ex animals had normal lung weight, the weight of ADAM17wt/wt lungs was 2.5 
times higher. Metastasis to the liver,  while less frequent,  appeared only in ADAM17wt/wt 
mice (Figure 4.1.1 b).
In order to determine if the observed effects were restricted to lung carcinoma cells or the 
observed effects were the consequence of reduced ADAM17 expression in the host, we 
injected B16F1 melanoma cells i.v. into ADAM17wt/wt and ADAM17ex/ex mice. Metastasis was 
analyzed 21 days post B16F1 injection. We were able to detected metastatic lesions in the 
lungs  and  livers  in  both  animal  groups  (Figure  4.1.2  a),  with  higher  incidence  in 
ADAM17wt/wt than in ADAM17ex/ex mice (Figure 4.1.2 b). Metastasis to the kidneys appeared 
only in ADAM17wt/wt mice (Figure 4.1.2 c). 
Figure 4.1.2 Metastasis to the lungs, liver and kidneys 21 days after B16F1 inoculation. a Lobes 
of the lung of ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) mice were dissected for better tumor visibility. Tumor 
lesions are visible in black, as a consequence of melanin production by B16F1 melanoma cells, b Livers of 3 
different ADAM17wt/wt and ADAM17ex/ex mice 21 days after inoculation with 5x105 B16F1 cells per mouse 
(liver metastasis are indicated by white arrows), c kidneys of ADAM17wt/wt and Adam17ex/ex mice 21 days 
post B16F1 injection (metastasis is indicated by red arrows).
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The number of microscopical tumors in the lungs of ADAM17wt/w mice was ten times higher 
compared  to  ADAM17ex/ex mice  (Figure  4.1.3).  Differences  in  lung  weight  were  not 
significant  between  these two  groups,  although lung  weight  of  wild  type animals  was 
increased compared to the lung weight of hypomorphic animals.
Figure 4.1.3 Quantification of tumor burden in B16F1 injected animals.  Number of surface lung 
tumors and lung weight of ADAM17wt/wt  (n=3) and ADAM17ex/ex  (n=3) mice 21 days after  injection with 
5x105 B16F1 cells  per  mouse.  n.s. -  not  significant  Data  are  represented as  means  ±  s.e.m.  ** 
p<0.005.
Survival of ADAM17ex/ex mice was dramatically increased in comparison to wild type mice 
after LLC injection. The survival rate of 50% for ADAM17wt/wt animals was observed 24 
days post LLC cell  injection (Figure 4.1.4), whereas ADAM17ex/ex mice were completely 
protected from metastasis induced death within observed time. 
Figure 4.1.4 Survival rate of LLC injected animals. Survival of  ADAM17wt/wt (n = 11) and  Adam17ex/ex 
(n = 7) mice injected with 5x105 LLC cells in a time course of 43 days.
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4.2  ADAM17 in the metastatic niche supports metastatic progression
We  analyzed  inflammatory  infiltrations  in  tumor  bearing  lungs  of  ADAM17wt/wt and 
ADAM17ex/ex mice  by  immunohistochemistry.  Tumor  lesions  in  the  lungs  were  readily 
detectable in HE staining 3 weeks after injection, in both LLC and B16F1 injected mice 
(Figure 4.2.1).  ADAM17wt/wt animals displayed a 5 fold increased number of  Ly6G/Gr1+ 
myeloid  cell  infiltrations  compared to  ADAM17ex/ex hypomorphic animals  (Figure  4.2.2). 
Ly6G/Gr1+ cells were detectable mainly in the tumorous part of the lung tissue. 
Figure  4.2.1  Infiltration  of  Gr1+ myeloid  cells  depends  on  ADAM17  in  the  metastatic  niche. 
Immunohistochemical stainings of  tumor bearing lungs 21 days post tumor cell  injection (5x10 5 per 
mouse); HE - Hematoxylin and eosin staining,  Gr1/Ly6G – granulocyte staining, F4/80 -  macrophage 
staining,  ADAM17wt/wt LLC  - wild type mice injected with LLC cells,  ADAM17wt/wt B16F1 – wild type 
mice  injected  withB16F1  cells,  ADAM17ex/ex LLC  – hypomorphic  mice  injected  with  LLC  cells, 
ADAM17ex/ex B16F1  – hypomorphic  mice  injected  withB16F1  cells;  (black  dot-line  represents  the 
boundary between tumorous and non-tumorous tissue, red arrows indicate the presence of Ly6G/Gr1+ 
cells, black arrows indicate B16F1 tumor cells).
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F4/80 immunohistochemistry performed on lung tissue from tumor bearing mice on 21 
days post-tumor cells injection revealed the absence of these cells in the lungs in both  
ADAM17wt/wt and ADAM17ex/ex mice (Figure 4.2.1). Interestingly, this was the case in both, 
LLC and B16F1 injected mice. 
Figure 4.2.2 ADAM17wt/wt tumor bearing lungs reveal increased infiltration of Ly6G/Gr1+ myeloid 
cells.  Quantification  of  Ly6G/Gr1+ cells  from 3  different  tumorous  areas  of  each  ADAM17wt/wt and 
ADAM17ex/ex mice 21 days after LLC inoculation analyzed from immunohistological sections.  Data are 
represented as means ± s.e.m.  * p<0.05.
We attempted to quantify the number of Ly6G/Gr1+ and F4/80+ cells in lung tissue sections 
of ADAM17wt/wt and ADAM17ex/ex mice inoculated with B16F1 cells, but unfortunately we 
were not successful. B16F1 cells express a substantial amount of melanin, thus displaying 
a black color in the sections. Ly6G/Gr1+ and F4/80+ cells after staining are recognized by 
dark brown color, therefore making the identification impossible due to mutual overlapping. 
Since we did not reveal F4/80+ cells in the non-tumorous areas, we concluded that these 
myeloid cells did not infiltrate into the lung tissue.
Using FACS analysis of tumor bearing lungs from ADAM17wt/wt and ADAM17ex/ex mice 21 
days after LLC cells injection, we determined the precise phenotype of Ly6G/Gr1+ myeloid 
cells. We could identify Ly6G/Gr1+ myeloid cells as CD11b+CD11c-Ly6G/Gr1+F4/80-  cells 
(Figure 4.2.3). This phenotype of myeloid cells correlated to a specific subset of MDSCs 
called granulocytic MDSCs.  Interestingly, the granulocytic subset of MDSCs was already 
described in several mouse tumor models and it strongly correlated with poor prognosis 
(Movahedi et al., 2008).
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Figure  4.2.3  ADAM17wt/wt tumor  bearing  lungs  display  stronger  infiltration  of  MDSCs. 
Representative FACS analysis of single cell suspensions from whole lung tissue of ADAM17wt/wt (n=3) 
and  ADAM17ex/ex (n=3)  mice  21  days  after  LLC  cells  inoculation  (5x105 cells  per  mouse)  a 
CD11b+Ly6G/Gr1+ MDSCs, b CD11c+Ly6G/Gr1+ MDSCs, c CD11b+F4/80+ MDSCs. Data are represented 
as means ± s.e.m. 
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4.3 Early phase of metastasis is marked with accumulation of Ly6G/Gr1+ but not 
F4/80+ cells
To  better  understand  if  reduced  tumor  growth  in  ADAM17ex/ex animals  was  due  to 
decreased MDSCs recruitment, we analyzed earlier time points post LLC cell injection for 
MDSCs infiltration. Mice were sacrificed 7 and 14 days after LLC cell injection. Although 
we were unable to detect tumor nodules in the lungs of one week injected mice, we could 
see an increased thickening of the inter-alveolar septae in immunohistochemical stainings 
in ADAM17wt/wt but not in ADAM17ex/ex tumor bearing lungs (Figure 4.3.1). 
Figure 4.3.1 Myeloid infiltrations in the lungs of ADAM17wt/wt and ADAM17ex/ex mice 7 days after 
LLC cells injection. ADAM17wt/wt and DAM17ex/ex mice were injected with 5x105 LLC cells per mouse. 
After 7 days, lungs were excised and analyzed by immunohistochemistry;  a  Hematoxylin and eosin 
(HE) staining of lung tissue one week post LLC inoculation (black arrows indicate for different thickness  
of inter-alveolar septae), b Immunohistochemical stainings for Ly6G/Gr1/+ and F4/80+ immune cells (red 
arrows indicate Ly6G/Gr1/+ cells in the lungs).
One of the causes for thickening of inter-alveolar septae could be the infiltration of immune 
cells into the interstitium. We could detect an increased infiltration of Ly6G/Gr1+ cells as 
early as one week after injection. However, we were unable to detect infiltration of F4/80 + 
cells (Figure 4.3.1).  Macroscopically visible tumors in the lungs of ADAM17wt/wt but not 
ADAM17ex/ex  mice, appeared as early as 14 days after LLC cell inoculation. The increase 
in thickening of inter-alveolar septae in wild type animals was even more evident 14 days 
after LLC cell inoculation (Figure 4.3.2). However, it was absent in hypomorphic mice. The 
amount  of  Ly6G/Gr1+  cell  infiltrations  was  markedly  increased in  ADAM17wt/wt animals, 
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whereas  it was barely detectable in ADAM17ex/ex animals. We could not detect F4/80+ cells 
in both mice groups (Figure 4.3.2). 
Figure  4.3.2  ADAM17wt/wt mice  show  increased  myeloid  infiltration  14  days  after  LLC  cells 
injection.  ADAM17wt/wt and DAM17ex/ex mice were injected with 5x105 LLC cells per mouse. After 14 
days,  lungs  were  excised  and  analyzed  by  immunohistochemistry; Hematoxylin  and  eosin  (HE) 
staining,  immunohistochemical  staining for  Ly6G/Gr1 and  F4/80  myeloid  cells and proliferating cell 
nuclear antigen (PCNA) 14 days after LLC cells injection from paraffin embedded tissue samples (red 
arrows indicate stronger thickening of inter-alveolar septae in wilde type mice than one week after LLC 
inoculation, black arrows indicate Ly6G/Gr1+ cell staining).
Taken together, these data demonstrate a correlation of tumor progression in wild type 
animals with Ly6G/Gr1+ MDSCs recruitment. Therefore, we concluded that reduced tumor 
growth in ADAM17ex/ex animals was due to decreased recruitment of MDSCs infiltration.
4.4  Tumor-bearing  lungs  of  ADAM17ex/ex mice  produce less factors  implicated  in 
MDSCs expansion and survival
We sought to analyze inflammatory cytokine and chemokine production in different time 
points post LLC cells injection. We took advantage of the Proteome Profile Murine cytokine 
antibody array (see the section 3.2.16) using lung tumor tissue lysates from ADAM17wt/wt 
and ADAM17ex/ex animals 21 days after LLC cells injection (Figure 4.4.1). We could detect 
significant differences in protein expression for several cytokines and chemokines between 
wild type and hypomorphic animals. The strongest difference was detectable in levels of 
CCL2/MCP-1.  Interestingly,  in  previous  studies,  CCL2/MCP-1  has  been  linked  to  the 
recruitment  and  expansion  of  MDSCs  at  the  tumor  site  (Sawanobori  et  al.,  2008). 
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Figure 4.4.1 Tumors of ADAM17wt/wt mice display increased production of inflammatory cytokines 
and  chemokines.  Tumorous  and  non-tumorous  parts  of  the  lung  tissue  21  days  after  LLC  cell 
inoculation from ADAM17wt/wt and ADAM17ex/ex mice were dissected, lysed (see the sections 3.1.4 and 
3.2.6) and 200 μg of protein lysate from tumorous part of the tissue was used for the Cytokine Array. 
Black and gray bars represent densitometric analysis; C5/C5a - complement component 5, sICAM1 - 
soluble  Intercellular  Adhesion  Molecule  1,  INF-γ -  interferon  gamma,  IL-1Ralpha –  interleukin  1 
receptor alpha,  IL-16 - interleukin 16,  CCL2/MCP1 - chemokine (C-C) motif 2/monocyte chemotactic 
protein1, CXCL9 - chemokine C-X-C motif ligand 9, CCL5 - chemokine (C-C) motif ligand 5, TIMP-1 - 
tissue inhibitor of metalloproteases 1,  IL-1alpha - interleukin 1 alpha,  IL-1beta -  interleukin 1 beta, 
CXCL10 - chemokine (C-X-C) motif ligand 10, KC/CXCL1 - chemokine (C-X-C) motif ligand 1, M-CSF - 
macrophage  colony  stimulating  factor,  CCL12/MCP5 -  chemokine  (C-C)  motif  ligand  12/monocyte 
chemotactic protein 5,  MIP-1a/CCL3 -  macrophage inflammatory protein 1 alpha/  chemokine (C-C) 
motif ligand 3, CXCL2 - chemokine (C-X-C) motif ligand 2, TREM 1 - triggering receptor expressed on 
myeloid cells 1.
We hypothesized that tumor cells could be the source of CCL2/MCP-1, thus contributing to 
strong  infiltration  of  CD11b+Ly6G/Gr1+Ly6C-F4/80-  MDSCs.  To  test  this  hypothesis,  we 
analyzed the cell culture medium of wtLLC and kdADAM17-LLC cells (see the section 4.9) 
for the production of CCL2/MCP-1. We were able to show that this chemokine  derived 
from tumor cells (Figure 4.4.2). Furthermore, we were able to validate the finding from 
Proteome Profile Murine cytokine antibody array for the protein expression of CCL2/MCP-
1 in tumor bearing lungs of ADAM17wt/wt and  ADAM17ex/ex mice by ELISA.
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Figure 4.4.2 CCL2/MCP-1 is predominantly produced by tumor cells. CCL2/MCP-1 concentration in 
200 μg of protein tissue lysates from ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) tumor-bearing lungs 21 
days after LLC cell inoculation measured by ELISA;  ex/ex T- tumorous part of the lung tissue from 
ADAM17ex/ex mice,  wt/wt T- tumorous part of  the lung tissue from ADAM17wt/wt mice,  wt/wt H- non-
tumorous part of the lung tissue from ADAM17wt/wt mice, ex/ex H- non-tumorous part of the lung tissue 
from ADAM17ex/ex mice,  wtLLC DMEM- filtered cell culture medium from wtLLC cells,  kdLLC DMEM- 
filtered  cell  culture  medium  from kdADAM17-LLC  cells,  DMEM was  used  as  a  control.  Data  are 
represented as means ± s.e.m. * p<0.05.
We were also able to detect CCL2/MCP-1 mRNA expression by qRT-PCR (Figure 4.4.3). 
Significant  differences  in  the  expression  of  CCL2/MCP-1  between  ADAM17wt/wt and 
ADAM17ex/ex mice appeared at early stages of metastasis. Only 7 days post LLC injection, 
with peaking after 14 days and sustaining until the final stage of metastasis in ADAM17wt/wt 
mice.  The  expression  of  CCL2/MCP-1  mRNA  was  slightly  increase  over  time  in 
ADAM17ex/ex mice.
Figure  4.4.3  Tumor  bearing  lungs  of  ADAM17wt/wt mice  reveal  high  mRNA  expression  of 
CCL2/MCP-1. RNA was extracted from the lungs of ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) mice at 
indicated  time  points  after  LLC  inoculation  (  5x105  cells per  mouse).  Quantitative  RT-PCR  was 
performed and mRNA was quantified as above, the amounts in non-inoculated lungs from ADAM17wt/wt 
and ADAM17ex/ex mice  were  set  to  value  of  1.0;  H -  healthy/non-tumorous  part  of  the  tissue,  T - 
tumorous part of the tissue. Data are represented as means ± s.e.m.  * p<0.05.
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To better understand the mechanism behind such a strong difference in myeloid infiltration 
between ADAM17wt/wt and ADAM17ex/ex mice,  the whole lung tissue,  from different  time 
points post LLC cells injection, was analyzed for the expression of genes implicated in the 
infiltration of granulocytic MDSCs.
Expression of CXCL2/MIP-2 has been previously correlated with infiltration of Ly6G/Gr1+ 
myeloid  cell  (Belperio  et  al.,  2002).  We  could  observe  that  mRNA  levels  of  the 
inflammatory chemokine CXCL2/MIP-2 was induced in earlier time points,  reaching the 
maximum of its expression 14 days after LLC inoculation and persisting with unsignificant 
decrease  through  metastasis  progression  in  ADAM17wt/wt mice  (Figure  4.4.4).  mRNA 
expression for CXCL2/MIP-2 remained unchanged through all time points in ADAM17ex/ex 
mice. 
Figure  4.4.4  Early  phase  of  metastasis  is  characterized  by  an  increased  transcription  of 
inflammatory chemokines. RNA was extracted from the lungs of ADAM17wt/wt (n=3) and ADAM17ex/ex 
(n=3) mice at  the indicated time points after  LLC inoculation ( 5x105  cells per mouse).  mRNA was 
quantified as above and the amounts in non-inoculated lungs from  ADAM17wt/wt and ADAM17ex/ex mice 
were set to 1.0 - basal level; H - healthy/non-tumorous part of the tissue, T - tumorous part of the tissue. 
Data are represented as means ± s.e.m.  *p<0.05,  ***p<0.001.
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Furthermore,  we observed that  the  inflammatory  chemokine CCL4/MIP-1β mRNA was 
induced only 20h after LLC inoculation (Figure 4.4.4) in both ADAM17wt/wt and ADAM17ex/ex 
mice, peaking 7 days post injection with a slight decrease in a late stage in ADAM17 wt/wt 
animals.  In  ADAM17ex/ex animals  the  expression  of  CCL4/MIP-1β  mRNA  was 
unsignificantly decreased over time. 
4.5  TNF-α is  released from the surface of  Ly6G/Gr1+ cells  in  the early phase of 
metastasis 
We were able to see a significant upregulation of gene expression of the pro-inflammatory 
cytokines TNF-α and IL-1β predominantly at early phases of metastasis in ADAM17wt/wt  but 
not in ADAM17ex/ex tumor bearing lungs (Figure 4.5.1).
Figure  4.5.1  TNF-α and  IL-1β are  upregulated  at  early  time  points  of  metastasis.  RNA was 
extracted from the lungs of ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) mice at the indicated time points 
after LLC inoculation ( 5x105  per mouse). mRNAs were quantified as above and the amounts in non-
inoculated lungs from ADAM17wt/wt and ADAM17ex/ex mice was set to 1; H - healthy/non-tumorous part of 
the tissue, T - tumorous part of the tissue. Data are represented as means ± s.e.m. * p<0.05, **p<0.005.
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Since we could observe stronger accumulation of Ly6G/Gr1+,  but not of F4/80+ cells in 
immunohistological stainings of tumor bearing lungs (section 4.3) in ADAM17wt/wt mice at 
early stage of lung metastasis, we speculated that infiltrated myeloid cells could be the 
source  of  the  pro-inflammatory  cytokines  TNF-α and  IL-1β.  In  order  to  confirm  this 
hypothesis, bone marrow cells were isolated from ADAM17wt/wt and ADAM17ex/ex mice, and 
differentiated to neutrophils and macrophages with rm G-CSF or rm M-CSF, respectively 
(see  the  sections  3.2.9  and  3.2.10).  Successful  differentiation  was  verified  by  FACS 
analysis  for  the presence  of  Ly6G/Gr1,  CD11b and F4/80  antigens (data  not  shown). 
Differentiated cells were stimulated with conditioned medium of LLC cells. Interestingly, we 
could detect TNF-α in the supernatant of wild type bone marrow derived macrophages 
(BMDM)  and  bone  marrow  derived  neutrophils  (BMDN).  However,  as  expected,  in 
supernatants of BMDMs and BMDNs derived from hypomorphic mice, the amount of TNF-
α was strongly reduced (Figure 4.5.2).  To confirm that  ADAM17 is the main sheddase 
responsible for the cleavage of  TNF-α from the surface of BMDNs upon stimulation with 
LLC conditioned medium, two hydroxamate-based ADAM17 inhibitors, GI and GW, were 
tested.  The inhibitor  GW280264X (GW) has the ability to potently  block the activity of 
ADAM10 and ADAM17, whereas GI254023X (GI) has the ability to block ADAM10 100-fold 
better then ADAM17 (Ludwig et al., 2005). 
Figure 4.5.2 BMDNs and BMDMs produce TNF-α upon stimulation with LLC cell supernatant. 
BMDNs  and  BMDMs  were  cultured  with  conditioned  medium of  LLC  cells  for  24h.  BMDNs  were 
cultured in presence or absence of 3μM GI or GW, and production of TNF-α was measured by ELISA; 
ex/ex - bone marrow cells from ADAM17ex/ex mice.  wt/wt - bone marrow cells from ADAM17wt/wt mice. 
Data are represented as means ± s.e.m.  ***p<0.001.
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As shown in Figure 4.5.2,  GI  reduced shedding of  TNF-α for  35% while GW reduced 
shedding of TNF-α for 90% from the surface of wild type BMDNs. These data indicate that 
ADAM17 is  responsible  for  supernatant-induced release of  TNF-α from the surface of 
myeloid cells.
Taken together, we can conclude that factors secreted by LLC cells stimulate infiltrated 
myeloid cells to releace TNF-α in an ADAM17 dependent manner.
4.6 ADAM17 generates proliferatory signals during lung metastasis
Proliferating Cell Nuclear Antigen (PCNA) is a nuclear protein that is a cofactor of DNA 
polymerase delta. PCNA acts as a homotrimer and helps to increase the processivity of 
leading strand synthesis during DNA replication. Frequently, it is used as marker for cell  
proliferation.
We performed PCNA immunohistological staining of paraffin sections from lung tissue of 
ADAM17wt/wt and  ADAM17ex/ex  mice  21  days  after  LLC  cell  injection  (Figure  4.6.1). 
Interestingly, in the tumorous part of wild type mice we detected 3.5 times more PCNA+ 
cells than in lung sections of hypomorphic mice. 
Figure 4.6.1 ADAM17 in the host contributes to cell proliferation. Immunohistological staining and 
number of PCNA+ cells from 3 different tumorous tissue areas of ADAM17wt/wt and ADAM17ex/ex mice 21 
days after LLC inoculation; black arrows indicate PCNA+ cells in the tumorous part of the tissue, red 
arrows indicate  PCNA+ cells in the non-tumorous part of the tissue;  PCNA - proliferating cell nuclear 
antigen. Data are represented as means ± s.e.m.  * p<0.05.
In  recent  publication,  Rivas and colleagues demonstrated that  TNF-α can induce  the 
proliferation of murine mammary tumor cells C4HD in vitro and in vivo (Rivas et al., 2008). 
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They  demonstrated  that  through  the  activation  of  p42/p44  MAPK,  JNK,  PI3-K/Akt 
pathways and NF-κB transcriptional activation, TNF-α induces proliferation of C4HD tumor 
cells.  Interestingly,  they  showed  that  blockage  of  TNFR1  or  TNFR2,  with  specific 
antibodies,  was enough to impair  TNF-α signaling.  Furthermore,  Rivas and colleagues 
demonstrated that administration of TNF-α in vivo supported C4HD tumor growth. Injection 
of  a  NF-κB  selective  inhibitor,  Bay  11-7082,  in  mice  resulted  in  regression  of  TNF-α 
promoted tumor growth.
We hypothesized that  LLC cells can proliferate upon TNF-α stimulation. Therefore, we 
stimulated LLC cells for 120h with different concentrations of rm TNF-α (Figure 4.6.2).  
                           TNF-α [ng/ml]         0          0,01       0,03        0,1         0,3           
Figure 4.6.2 TNF-α increases proliferation of wild type LLC cells at early time points. 5x105 cells 
per well were seeded into 6 well plates; cells were cultured in DMEM supplemented with 0,5% FCS for 
120h in the presence or absence of rmTNF-α; cells were counted after 24, 48, 72 and 120h. RNA was 
isolated from the cells stimulated for 24h with different concentrations of rmTNF-α and gene expression 
for ICAM-1, MMP-9, VEGFR-1 and 2, TGF-α and PCNA was analyzed by semiquantitative RT-PCR; 
ICAM-1 – intercellular adhesion molecule 1, MMP-9 – matrix metalloprotease 9, VEGFR-1/-2 – vascular 
endothelial growth factor receptor transcript variants 1 and 2, TGF-α – transforming growth factor alpha, 
PCNA- proliferating cell nuclear antigen. Data are represented as means ± s.e.m. ** p<0.005. 
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Interestingly, preliminary data suggest that 24h after TNF-α stimulation, all stimulated LLC 
cells  had  a  significantly  higher  proliferation  rate  than  TNF-α  unstimulated  cells. 
Furthermore,  in  the  first  24h  of  stimulation,  we  could  detect  a  TNF-α concentration 
dependent  mRNA upregulation  of  intercellular  adhesion  molecule  1  (ICAM-1),  matrix 
metalloprotease 9 (MMP-9) and vascular endothelial growth factor receptor 2 (VEGFR-2). 
Furthermore,  48h  after  stimulation,  proliferation  rate  of  TNF-α  stimulated  and  non-
stimulated cells equalized. At later time points proliferation of all TNF-α stimulated cells 
was significantly reduced compared to unstimulated cells.
Taken into account that TNF-α was upregulated in the lungs shortly after LLC injection, we 
concluded that TNF-α can be a proliferatory stimulus for cancer cells at early stages of 
metastasis.
Receptor  tyrosine  kinases  (RTKs)  are  high-affinity  cell  surface  receptors  for  many 
polypeptide growth factors, cytokines and hormones. Receptor tyrosine kinases have been 
shown not only to be the key regulators of normal cellular processes but also to have a 
critical role in the development and progression of many types of cancer (Zwick et al.,  
2001). Ser/Thr kinase extracellular-signal-regulated kinase (ERK) is activated downstream 
of several RTKs. 
To investigate proliferatory signals in ADAM17wt/wt and ADAM17ex/ex tumor bearing lungs, we 
analyzed ERK phosphorylation by Immuno blot analysis (Figure 4.6.3). 
Figure 4.6.3 Tumor bearing lungs of ADAM17wt/wt mice show activation of ERK kinase. 200 μg of 
protein lysate from the lung tissue from 7, 14 and 21 days after LLC cells injection in ADAM17wt/wt and 
ADAM17ex/ex mice was used for Immuno blot analysis. Antibodies against P-ERK1/2 and ERK1/2 were 
used (see the section 3.1.8) for Immunoblot analysis; 1w -1 week,  2w -2 weeks,  3w -3 weeks, ex/ex 
-protein  lysates  from  ADAM17ex/ex  mice,  wt/wt  -protein  lysates  from  ADAM17wt/wt  mice,  ERK1/2 - 
extracellular-signal-regulated kinase, P-ERK1/2 - phosphorylated extracellular-signal-regulated kinase.
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Interestingly, tumorous parts of the lung tissue from wild type animals 21 days post LLC 
cells injection, revealed increased ERK phosphorylation, in wild type animals compared to 
hypomorphic animals.
To better understand which receptor tyrosine kinase was implicated in ERK activation, we 
performed a phospho-RTK antibody array (RTK array) (see the section 3.2.17). 
Figure 4.6.4 Phospho-RTK antibody array from lung tissue of ADAM17wt/wt and ADAM17ex/ex mice 
2 and 3 weeks post LLC cell injection. 200μg of protein lysate was used for the Phospho-RTK array; 
quantification  of  receptor  phosphorylation  in  the  tumor  lysates  3  weeks  after  LLC inoculation  was 
measured by densitometry. (Quantification of receptor phosphorylation in the lysates 2 weeks after LLC 
inoculation not shown); EGFR - epidermal growth factor receptor,  FGFR 2 - fibroblast growth factor 
receptor 2, FGFR 3 - fibroblast growth factor receptor 3, Insulin R - insulin receptor, IGF-1R  - insulin-
like growth factor receptor 1, Axl - Axl receptor tyrosine kinase, Mer - Proto-oncogene tyrosine-protein 
kinase MER,  HGF R  - hepatocyte growth factor receptor,  MSP R -  macrophage stimulating protein 
receptor, PDGFR alpha - platelet-derived growth factor receptor alpha, PDGFR beta - platelet-derived 
growth factor receptor beta, SCFR - stem cell factor receptor, Flt3 - Fms-like tyrosine kinase 3, M-CSF 
R - macrophage colony stimulating factor receptor, Tie1 - Tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1, Tie 2 - Tyrosine kinase with immunoglobulin-like and EGF-like domains 2, Trk A - 
neurotrophic tyrosine kinase receptor type 1, Trk B - neurotrophic tyrosine kinase receptor type 2, Trk 
C - neurotrophic tyrosine kinase receptor type 3, VEGFR1 - vascular endothelial growth factor receptor 
1,  VEGFR2 -  vascular  endothelial  growth factor receptor 2,  VEGFR3 -  vascular  endothelial  growth 
factor receptor 3, MuSK - Muscle-Specific Kinase.
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We used tumor lysates from animals 14 and 21 days post LLC injection for the phospho-
RTK antibody array (Figure 4.6.4). We detected slight difference in the phosphorylation of 
ErbB3  and  ErbB4,  which  belong  to  the  EGFR  family.  However,  the  most  striking 
differences in the phosphorylation of RTKs between ADAM17wt/wt and ADAM17ex/ex tumor 
bearing  lungs  were  seen  in  PDGFRα and  Axl.  Phosphorilation  of  both  RTKs  was 
detectable 2 and 3 weeks post LLC injection. 
Taken together, these data indicate that ADAM17 expression in the host tissue correlates 
with Axl, PDGFR-α and ErbB3/4 activation.
4.7 ADAM17 is required for Notch activation at early phases of metastasis 
ADAM17 has been implicated in the shedding of Notch receptor ligand Jagged-1 (Lu et al, 
2013). As soluble Jagged-1 can induce cancer stem cell (CSC) phenotype in disseminated 
cancer  cells,  we analyzed Notch activation  in tumor  bearing lungs of  ADAM17wt/wt and 
ADAM17ex/ex mice  at  different  time  points.  We were  unable  to  detect  Notch-1  ICD by 
Immunoblotting and immunohistochemistry (data not shown). However, we could see an 
upregulation of the Notch-target genes Hes1 and Hey1 20h and 7 days after LLC cell  
injection (Figures 4.7.1 and 4.7.2). 
Figure 4.7.1 ADAM17ex/ex mice show decreased activation of Notch signaling in an early phase of 
metastasis.  RNA was extracted from the lungs of ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) mice at 
indicated time points after LLC inoculation (5x105 cells per mouse). Real time PCR was performed and 
mRNA  was  quantified  as  above,  the  amounts  in  non-inoculated  lungs  from   ADAM17wt/wt and 
ADAM17ex/ex mice were given value of 1.0 - basal level; H - healthy/non-tumorous part of the tissue, T - 
tumorous part of the tissue) Hey 1 - Hairy/enhancer-of-split related YRPW motif like protein 1, Hes 1 - 
Hairy/Enhancer and Split 1. Data are represented as means ± s.e.m.  * p<0.05. 
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Figure 4.7.2 ADAM17ex/ex mice show decreased activation of Notch signaling at early phase of 
metastasis.  RNA was extracted from the lungs of ADAM17wt/wt (n=3) and ADAM17ex/ex (n=3) mice at 
indicated time points after LLC inoculation (5x105 cells per mouse). Real time PCR was performed and 
mRNA  was  quantified  as  above,  the  amounts  in  non-inoculated  lungs  from   ADAM17wt/wt and 
ADAM17ex/ex mice were given value of 1.0 - basal level; H - healthy/non-tumorous part of the tissue, T - 
tumorous part of the tissue) Hey 1 - Hairy/enhancer-of-split related YRPW motif like protein 1, Hes 1 - 
Hairy/Enhancer and Split 1. Data are represented as means ± s.e.m.  * p<0.05, ** p<0.005. 
4.8 IL-6 trans-signaling does not promote lung metastasis 
IL-6 can act via IL-6 classic and IL-6 trans-signaling. Binding of IL-6 to the membrane 
bound IL-6 receptor  induces the recruitment  of  two gp130 molecules and downstream 
activation of intracellular signaling cascades. This process is marked IL-6 classic signaling. 
Binding of IL-6 to soluble IL-6R (sIL-6R) induces formation of IL-6/sIL-6R complex which 
can interact with gp130 molecule and induce its dimerization and downstream activation of 
intracellular signaling cascades. This process is marked IL-6 trans-signaling. 
Interestingly,  gp130  molecule  exists  in  a  soluble  form  (sgp130).  sgp130  molecule  is 
predominantly  generated  by  alternative  splicing.  It  can  associate  with  the  IL-6/sIL-6R 
complex and inhibit signaling via membrane bound gp130 (Montero-Julian, 2001; Mueller-
Newen et al., 1998). Jostock and colleagues postulated that sgp130 molecule acts as a 
natural inhibitor of IL-6 trans-signaling (Jostock et al., 2001). Therefore, a designer protein, 
was generated by fusion of the Fc part of a human IgG to extracellular portion of gp130 
molecule. The resulting protein, termed sgp130Fc, is a preformed homodimer and strongly 
resembles the endogenous receptor on the living cell. Interestingly, Becker and colleagues 
demonstrated  that  administration  of  sgp130Fc  has  tumor  suppressor  activity  in  colon 
cancer  (Becker  et  al.,  2004).  Furthermore,  Zhang  and  colleagues  were  able  to  show 
62
Hey 1
fo
ld
 in
du
ct
io
n
Results                                                                                                                                     
that during severe acute pancreatitis (SAP) IL-6 trans-signaling promotes acute lung injury 
(ALI), as secondary effect of SAP (Zhang et al., 2013). They were able to reduce SAP 
induced ALI by administration of sgp130Fc protein. Symptoms of ALI very much resembled 
to  symptoms  of  strong  lung  inflammation  characteristic  for  initial  phases  of  lung 
metastasis.
We hypothesized that inhibition of IL-6 trans-signaling could decrease the inflammatory 
response and delay metastasis progression in LLC model of experimental metastasis. To 
test this hypothesis, we used sgp130Fc transgenic mice, which express sgp130Fc under 
the control  of  the liver-specific  PEPCK (phosphoenolpyruvate carboxykinase) promoter. 
However,  sgp130Fc protein is distributed via the bloodstream to all  organs except the 
brain (Rabe et al,  2008). Lung metastasis was induced via i.v. injection of LLC cells in 
sgp130Fc and control, C57Bl6/N mice. Lung and liver tissues were analyzed 21 days post  
LLC injection (Figure 4.8.1).
Figure 4.8.1 Experimental metastasis with LLC cells in sgp130Fc and C57Bl6/N mice. Lungs of 
sgp130Fc (n=3)  and C57Bl6/N (n=3)  mice 21 days after  LLC inoculation with  5x105 LLC cells  per 
mouse. Liver metastasis in one sgp130Fc mouse is indicated with white arrow. Data are represented as 
means ± s.e.m.
21 days after LLC cells inoculation, we did not detect any difference in lung appearance 
and tumor burden in sgp130Fc and C57Bl6/N mice. Total lung weight was 3 times above 
the average lung weight, with no significant difference between sgp130Fc and C57Bl6/N 
63
Lu
ng
 w
ei
gh
t [
m
g]
C57Bl6/N sgp130Fc
Results                                                                                                                                     
mice.  Metastasis  to  the  liver  appeared  only  in  one  sgp130Fc  mouse  (Figure  4.8.2  – 
sgp130Fc liver).
We performed immunohistochemical stainings from tumor bearing lungs of sgp130Fc and 
C57Bl6/N mice (Figure 4.8.2). 
                           HE                                     Gr1/Ly6G                                       F4/80
Figure 4.8.2 sgp130Fc and C57Bl6/N mice show same tumor burden. Immunohistological stainings 
of lung tissue from sgp130Fc and C57Bl/6N tumor bearing lungs 21 days after LLC inoculation; HE - 
haematoxilyn and eosin staining,  Ly6G - staining for granulocytes,  F4/80 - staining for macrophages 
white arrow indicate liver tumor of sgp130Fc mice; sgp130Fc liver - HE stainings of liver metastasis in 
sgp130Fc mice. 
From immunohistochemical stainings we concluded that there was no difference in the 
level of lung damage between sgp130Fc and control mice. We were able to detect strong 
infiltration of Ly6G/Gr1+ myeloid cells in both sgp130Fc and C57Bl6/N lung tissue. We 
could not detect F4/80+ cells in both mice groups. 
According to these data we can conclude that sgp130Fc does not play a protective role in 
lung metastasis.
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4.9 ADAM17 in tumor cells contributes to tumor cell growth in vitro and metastatic 
growth in vivo
In  the  model  of  experimental  metastasis  with  LLC  cells  we  could  demonstrate  the 
importance of ADAM17 in the stroma for metastatic progression and spread. Next, we 
were interested weather ADAM17 in the tumor cells was equally important for metastatic 
growth. To test this assumption, we generated  LLC cells with a stable ADAM17 knock 
down (kdADAM17-LLC) by lentiviral transduction (see the sections 3.2.2 and 3.2.3). The 
lentiviral vector, termed sh17-pLeGO-C/BSD, contained, as well, a cassette coding for the 
fluorescent  protein  mCherry  (the  'm'  in  the  name denotes  its  monomer  configuration).  
mCherry is a monomeric fluorescent protein with peak absorption/emission at 587 nm and 
610 nm, respectively.  It  matures quickly,  within 15 minutes,  allowing it  to be visualized 
soon after translation.
After  LLC  cell  transduction,  we  selected  single  cell  clones,  positive  for  mCherry 
expression,  expanded and tested them for  ADAM17 protein  and mRNA expression by 
Immunoblotting (WB) and RT-PCR, respectively (Figures 4.9.1).
Figure  4.9.1  ADAM17 protein  and mRNA expression in  different  kdADAM17-LLC clones.  106 
kdADAM17LLC cells were seeded into 6 well plates in DMEM supplemented with 10% FCS. After 24h 
mCherry protein expression was observed and photographed under fluorescent microscope (red cells 
in the upper right picture panel) and cells were lysed. After 24h RNA from kdADAM17-LLC cells, clone 
H,  was  isolated  and  RT-PCR  for  ADAM17  and  β-actin  was  performed.  SDS-polyacrylamide  gel 
electrophoresis from the cell lysates was performed on 8% gel. Immuno-blot was performed with anti-
ADAM17 antibody; + contr. - lysate of 106 ADAM17 wild type cells used as a positive control, - contr. - 
lysate of 106 ADAM17 knock down colon cancer cells (kdADAM17-CMT93) used as a negative control, 
proADAM17 - ADAM17 with pro-domain, mADAM17 - mature ADAM17, wt - wild type LLC cells, F, Z, 
R, D,Q, H, G -  different clones of kdADAM17-LLCs.
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From the Immunoblot analysis we could conclude that clones R and H did not express pro-
ADAM17,  while  only  clone  H,  but  not  clone  R,  expressed  mature  ADAM17.  Both 
kdADAM17-LLC cell clones had significantly reduced proliferation rate compared to wild 
type  LLC  cells  (data  not  presented  for  the  clone  R).  Interestingly,  clone  R  grew  less 
efficiently than clone H. Therefore, we decided to use the clone H for further experiments.
Proliferation of unstimulated kdADAM17-LLC cells was significantly reduced compared to 
unstimulated wild type LLC cells  (wtLLC).  Proliferation rates were significantly different 
already in the first 24h (Figure 4.9.3). We observed that the difference in proliferation was 
increasing over time. From this experiment we could conclude that ADAM17 in the tumor 
cells is necessary for tumor cell growth.
Figure 4.9.2 kdADAM17-LLC cells grow significantly slower than wild type LLC cells. 5x105 cells 
per well were seeded into 6 well plates  in DMEM supplemented with 10% FCS and P/S; cells were 
cultured  for  144h;  number  of  cells  was  analyzed  24h,  48h,  72h  and  144h  after  seeded.  Each 
measurement was performed in triplicate.  Data are represented as means  ±  s.e.m.  * p<0.05,  *** 
p<0.001.
In preliminary experiments, we analyzed the potential of kdADAM17-LLC cell to induce 
lung metastasis in vivo. kdADAM17-LLC cells were injected i.v. via tail vein into C57Bl6/N 
mice and the lung tissue was analyzed 21 days post injection (Figure 4.9.4). As a control 
for successful i.v. injection, we injected wtLLC cells into C57Bl6/N mice.
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Figure 4.9.3 ADAM17 in tumor cells is necessary for metastatic growth in vivo. 5x105 kdADAM17-
LLC or wtLLC cells per mouse were injected in C57Nl6/N mice; 3 mice per each group were used; 
lungs were excised and photographed 21 days after cells inoculation;  mice within the same group 
displayed an equal effect in lung metastases, therefore from each group, lung picture from a single 
mouse is presented here; wtLLC – C57Bl6/N mice injected with wild type LLC cells, kdADAM17-LLC – 
C57Bl6.N mice injected with kdADAM17-LLC cells.
We could show that lacking of ADAM17 in the tumor cells resulted in null development of 
lung metastasis. This was reflected in a significant difference in a total lung weight (Table 
4.9.1) between C57Bl6/N mice injected with wtLLC and kdADAM17-LLC cells (clone H).
Mouse Lung weight [mg]
C57Bl6/N  1 with kdADAM17-LLC 180
C57Bl6/N  2 with kdADAM17-LLC 200
C57Bl6/N  3 with kdADAM17-LLC 190
C57Bl6/N  1 with wtLLC 480
C57Bl6/N  2 with wtLLC 520
C57Bl6/N  3 with wtLLC 570
Table 4.9.1 Lung weight of C57Bl6/N mice 3 weeks after injection of wild type or kdADAM17-LLC 
cells. 5x105  cells were injected via the tail vain into C57Bl6/N mice. 21 days post tumor cells injection 
lungs were excised and measured.
We were able to detect the presence of kdADAM17-LLC cells in the tumor bearing lungs, 
performing RT-PCR for the expression of mCherry mRNA (Figure 4.9.4).
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Figure  4.9.4  mRNA  expression  of  mCherry  in  the  lungs  of  C57Bl6/N  mice  injected  with 
kdADAM17-LLC cells.  RNA was extracted from the whole lung tissue of 3 different C57Bl6/N mice 
(mouse 1, 2, 3) injected with kdADAM17-LLC cells 21 days post injection. Semiquantitative RT-PCR 
was performed for the expression of mCherry protein; + contr. - RNA from kdADAM17-LLC cells.
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5 Discussion
5.1 ADAM17 in model of experimental metastasis
In the present study we used a murine model of experimental metastasis to investigate the 
role  of  ADAM17  in  metastatic  progression.  We  used  ADAM17  hypomorphic  mice 
(ADAM17ex/ex) which express barely detectable level of ADAM17 protein (Chalaris et al., 
2010), thus mimicking the condition where ADAM17 is inhibited in the host. To induce lung 
metastasis we injected LLC lung carcinoma or B16F1 melanoma cells through the tail vein. 
We  were  able  to  show  that  three  weeks  after  inoculation  with  LLC  or  B16F1  cells,  
ADAM17wt/wt  animals displayed a significantly higher number of macroscopical tumors in 
the lungs than ADAM17ex/ex   animals, independent of the tumor entity. Furthermore, lung 
weight of control  mice was significantly increased while the lung weight of ADAM17ex/ex 
hypomorphic mice was in the normal range of 200±50 mg. In the case of B16F1 injection, 
all  control animals had multiple liver and kidney metastasis, while 67% of hypomorphic 
animals had single liver and no kidney metastasis. 
A remarkable difference was seen in the survival rate of ADAM17ex/ex mice compared to 
ADAM17wt/wt mice  within  an  observed  time  of  43  days  after  LLC  cell  inoculation.  All  
ADAM17ex/ex mice were alive, while 80% of wild type mice died in this time period. 
Our  results  indicate  that  ADAM17 in  the  metastatic  niche  plays  an important  role  for 
metastatic  progression  via  proliferatory,  inflammatory  and  immunosuppressive  stimuli 
(Figure 5.1).
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Figure 5.1 ADAM17 contribution to lung metastasis. ADAM17 in the metastatic niche plays a crucial 
role for progression of lung metastasis. It influences inflammatory and proliferatory signals via shedding 
of different substrates. Shedding of TNF-α induces early inflammatory response and transcription of 
chemokines necessary for myeloid cell infiltration. At early phases of lung metastasis increased amount 
of TNF-α can influence LLC cell proliferation, as well.  Infiltration of myeloid cells (MDSCs) leads to 
immunosuppression.  ADAM17 sheds growth  factors  implicated in  RTK EGF family  activation,  thus 
contributing to cell proliferation and survival. Cartoon of ADAM17 was taken from Scheller et al., 2011.
5.2. ADAM17 in the metastatic niche is important for inflammatory signals
We were able to demonstrate by quantitative real time PCR from whole lung tissue that 
TNF-α and  IL-1β are the major inflammatory mediators responsible for the induction of 
lung damage in  early  stages of  metastasis.  qRT-PCR analysis  of  genes implicated  in 
inflammatory response clearly demonstrated significant upregulation, even up to 10 times, 
of  TNF-α  and  IL-1β  in  ADAM17wt/wt compared  to  ADAM17ex/ex mice.  The  strongest 
difference in TNF-α mRNA expression was 20h and 7 days post LLC cell injection, with 
tendency to decrease almost to a basal level in later time points. Interestingly, we could 
demonstrate  that  soluble  TNF-α  (sTNF-α)  derives  from  myeloid  cells  in  vitro. 
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Bone  marrow  derived  macrophages  (BMDM)  produced  TNF-α  upon  stimulation  with 
conditioned medium of LLC cells. BMDMs from ADAM17wt/wt mice produced 50 times more 
sTNF-α  than  BMDMs  from  ADAM17ex/ex mice.  However,  we  were  not  able  to  detect 
macrophages stained against F4/80 antigen in lung tissue sections in all four time points. 
Surprisingly,  we could detect  cells  positive for Ly6G/Gr1 antigen in immunohistological 
analysis from all time points. 
Thus, we hypothesized, that bone marrow derived granulocytes/neutrophils (BMDN) might 
be  the  source  of  TNF-α in  tumor  bearing  lungs.  Stimulation  of  BMDNs  with  LLC 
conditioned  medium  resulted  in  the  production  of  TNF-α.  Interestingly,  BMDNs  from 
ADAM17wt/wt mice produced 4 times more sTNF-α than BMDMs when stimulated with the 
same conditioned medium. At the same time, BMDNs from ADAM17wt/wt  mice produced 4 
times more sTNF-α than BMDNs from ADAM17ex/ex mice. Our data demonstrated that the 
generation of sTNF-α by ADAM17 from the surface of wild type BMDNs was efficiently 
blocked (~90%) by  combined ADAM10 and  ADAM17 inhibitor,  GW280264X,  while  the 
ADAM10 specific inhibitor, GI254023X, was not as efficient in blocking of TNF-α shedding 
(~30%). 
Interestingly,  the group of  M. Karin  identified TNF-α as a major  inducer  of  metastasis 
progression in a model of experimental metastasis with LLC cells (Kim et al., 2009). They 
could  show  that  TNF-α-/- mice  had  increased  survival  rate,  less  tumors  and  reduced 
infiltration of myeloid cells into the lungs. However, ADAM17ex/ex mice display even higher 
protection  rate  than  TNF-α-/- mice.  Nevertheless,  they  excluded  IL-6,  as  inducer  of 
inflammation  and  proliferation  in  metastasis  in  this  model.  Using  IL-6 -/- mice  they 
demonstrated that  metastasis  progression was not  delayed or reduced,  but  it  was the 
same like in control mice. As well, they demonstrated that LLC cells, among several types 
of  cancer  cells,  were  the  most  potent  activators  of  macrophages  for  TNF-α  and  IL-6 
production. 
Our  results  indicate  that  sTNF-α  in  our  metastasis  model  was  mainly  generated  by 
infiltrated myeloid  cells.  We hypothesized that  abrogation of  TNF-α shedding from the 
surface of myeloid cells by ADAM17 would lead to reduced inflammation and subsequently  
reduced  metastasis  progression.  To  validate  this  hypothesis,  we  will  use  a  model  of 
experimental metastasis with LLC cells in ADAM17-LysM-Cre conditional knock out mice, 
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which lack ADAM17 in myeloid cells. 
During tumor development, myeloid cells are recruited and can be converted into potent 
immunosuppressive  cells.  Immature  myeloid  cells  with  the  same  phenotype  as 
immunosuppressive cells are generated in the bone marrow of healthy individuals and 
differentiated into mature myeloid cells without causing any kind of immunosuppression. 
However, in a cancerous state, myeloid cells are differentiated into pathological myeloid 
derived  suppressor  cells  (MDSCs)  which  can  suppress  the  host  anti-tumor  immune 
response. Human granulocytic MDSCs isolated from peripheral blood of patients suffering 
from breast, colon or lung cancer were indicators of poor prognosis (Greten et al., 2011). 
Following  tumor progression through 14 and 21 days post LLC cell inoculation, we were 
able to detect an increase in the number of Ly6G/Gr1+ cells in immunohistological staining 
from tumor bearing lungs of both ADAM17wt/wt  and ADAM17ex/ex animals. We were able to 
see the same effect in Ly6G/Gr1+ cell infiltration in the tumor bearing lungs of ADAM17wt/wt 
and ADAM17ex/ex animals 21 days after inoculation with B16F1 melanoma cells.  Tumor 
bearing  lungs  of  ADAM17wt/wt mice  had  stronger  infiltration  of  granulocytic  MDSCs 
characterized  with  CD11b+Ly6G/Gr1+F4/80-CD11c-  phenotype  (Youn  et  al.,  2008),  than 
tumor bearing lungs of ADAM17ex/ex mice.
ADAM17 has been shown to have an important role in immunosuppression of T-cells by 
MDSCs. Namely, ADAM17 on the surface of MDSCs can cleave L-selectin (CD62L) on the 
surface of  naïve CD4+ and CD8+ T-cells  in the tumor (Hanson,  2009).  Shedding of  L-
selectin from the surface of naïve CD4+ and CD8+ T-cells disables recirculation of T cells to 
the lymph nodes, thus reducing host immune response against the tumor. Unfortunately,  
until  now we did  not  determine the  presence of  CD4+ and CD8+ T-cells  in  the  tumor 
bearing  lungs  of  ADAM17wt/wt and  ADAM17ex/ex  mice.  We  hypothesized  that 
immunosuppression  is  much  stronger  in  tumor  bearing  lungs  of  ADAM17wt/wt than  in 
ADAM17ex/ex mice. Therefore, we assume that hypomorphic mice should have significantly 
higher number of CD4+ and CD8+ T-cells in tumor bearing lungs than wild type mice.
To better understand the mechanism of myeloid cells attraction into tumor bearing lungs, 
we performed quantitative real time PCR for mRNA expression of different chemokines 
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at  all  time  points  post  LLC  cell  injection.  We  found  increased  transcription  of  the 
inflammatory chemokine CCL4/MIP-1β only 20h after LLC inoculation in whole lung tissue 
from ADAM17wt/wt mice. Expression of CCL4/MIP-1β in ADAM17ex/ex lung tissue was on a 
basal level through all four time points. Interestingly, our data correlated with previously 
published  data  that  over-expression  of  IL-1β can  induce  production  of  CCL4/MIP-1β 
(Zhang et al., 2003). We could demonstrate that IL-1β mRNA expression was significantly 
upregulated in tumor bearing lungs of ADAM17wt/wt mice in all time points peaking 7 days 
post injection. Interestingly, IL-1β can be induced by TNF-α. We were able to detect an 
increased expression of TNF-α as early as 20h after LLC cell injection in wild type animals. 
We  can  hypothesize  that  sTNF-α,  generated  by  ADAM17  shedding,  induces  IL-1β 
expression thus  indirectly  contributing  to  CCL4/MIP-1β  production.  CCL4/MIP-1β 
chemokine is important for T-cell infiltration.
It is possible that secretion of TNF-α and IL-1β early after tumor cell extravasation induces 
expression  of  CXCL2/MIP-2  resulting  in  attraction  of  myeloid  cells  to  the  lungs. 
CXCL2/MIP-2 is a very potent neutrophil chemoattractant, and it has been correlated with 
infiltration of neutrophils before, in a model of acute lung injury induced by LPS (Gupta et  
al., 1996). 
One of the factors implicated in attraction, expansion and activation of MDSCs in cancer is 
CCL2/MCP-1. Isolating RNA from the whole lung tissue of ADAM17wt/wt and ADAM17ex/ex 
mice from all time points post injection, we were able to demonstrate an upregulation of 
CCL2/MCP-1 gene expression in control mice. Significant differences in the expression of 
CCL2/MCP-1 gene in ADAM17wt/wt and ADAM17ex/ex mice appeared 20h post LLC injection, 
peaking after 14 days and sustaining until the final stage of metastasis. The expression of 
CCL2/MCP-1 remained unchanged through all time points in ADAM17ex/ex mice. 20h post 
LLC cell injection CCL2/MCP-1 was 15 times more expressed in tumor bearing lungs than 
in  the  untreated  lungs  of  ADAM17wt/wt mice.  Finally,  we  wanted  to  ascertain  that 
upregulation  of  CCL2/MCP-1  gene  expression  lead  to  increased CCL2/MCP-1  protein 
production. We were able to confirm that protein expression from whole lung tissue of 
ADAM17wt/wt mice was significantly increased compared to ADAM17ex/ex mice in the final 
stage of  metastasis.  Furthermore,  we were  able  to  show that  produced CCL2/MCP-1 
mainly  derived  from  tumor  cells.  This  finding  supported  already  published  data 
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(Sawanobori et al., 2008). 
High  CCL2/MCP-1  serum  levels  in  breast  cancer  patients  correlated  with  disease 
progression and poor prognosis (Soria et al., 2008). Soria and colleagues demonstrated 
that MDSCs are recruited to the tumor via CCL2/CCR2 pathway (Huang et al., 2007). They 
isolated cancerous tissue from patients suffering from breast, ovarian or gastric cancer and 
demonstrated that migration of MDSCs was depended of CCL2/CCR2 pathway. Namely, 
they used a transwell aparatus where they placed tumor samples from patients in a lower 
chamber, and MDSCs isolated from the same patients blood in upper chamber. They could 
show significant reduction in transmigration of MDSCs towards tumorous tissue when anti-
CCL2 or  anti-CCR2 antibody was  used.  Interestingly,  production  of  CCL2/MCP-1  was 
already  recognized  in  murine  tumor  models  where  LLC  and  B16F1  cells  were  used 
(Gabrilovich et al., 2009). 
Our  data  demonstrate  that  ADAM17  plays  an  important  role  for  the  infiltration  of 
immunosuppressive myeloid cells to tumor bearing lungs initially via CXCL2/MIP-2 and in 
later stages via CCL2/MCP-1 chemokine production. This supports already published data 
that CCL2/MCP-1, which derives from the tumor cells, has implication in MDSC infiltration 
in later stages of cancer development (Huang et al., 2007). 
Since CCL2/MCP-1 mainly derived from cancer cells, we hypothesize that the difference in 
CCL2/MCP-1 expression between ADAM17wt/wt and ADAM17ex/ex mice correlates with the 
different number of tumor cells in the lungs. The difference in tumor cell number could be 
explained  by  a  different  ability  of  tumor  cells  to  extravasate  into  the  lung  tissue. In 
endothelial and epithelial cell junctions, a variety of proteins are involved. JAM-A is located 
at tight endothelial and epithelial junctions and it has been shown to be a substrate of  
ADAM17 (Dreymueller et  al.,  2012).  When it  is  shed,  like in ADAM17wt/wt animals,  the 
extravasation of tumor cells can be unimpeded and when JAM-A is not shed, potentially 
like in ADAM17ex/ex animals, extravasation of tumor cells can be reduced. To validate this 
hypothesis,  we  will  use  a  model  of  experimental  metastasis  with  mCherry-LLC  cells. 
mCherry-LLC cells are LLC cells  stably  transduced with an empty vector  containing a 
cassette coding for the fluorescent protein mCherry. Since we were successful in tracing 
the mCherry labeled kdADAM17-LLC cells via RT-PCR (section 4.9), we want to use this 
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method to investigate is tumor cells extravasation altered in ADAM17ex/ex mice.
5.3 ADAM17 enhances metastatic progression via proliferatory stimuli
We were able to detect significantly higher number of PCNA+ cells in tumor bearing lungs 
of ADAM17wt/wt than ADAM17ex/ex animals.  PCNA+ areas in the lung tissue were mainly 
tumorous areas, while the surrounding tissue was less proliferating. In the line of these 
findings, we could detect an increased phosphorylation of ERK1/2 kinase 21 days after 
injection. Impressive difference in activation of ERK1/2 kinase between ADAM17wt/wt  and 
ADAM17ex/ex mice was mainly in the tumorous part of the lung tissue. Interestingly, we were 
not  able  to  detect  any  phosphorylation  of  ERK1/2  kinase  in  tumor  lysates  from 
hypomorphic mice. To better understand from which signaling pathway such  significant 
difference  derived,  we  tested  tumor  lysates  from  2  and  3  weeks  injected  mice  for 
phosphorylation  of  different  receptor  tyrosine  kinases  using  a  Phospho-RTK  antibody 
array. We could detect increased phosphorylation of PDGFR-α and Axl in tumor samples 
of ADAM17wt/wt compared to ADAM17ex/ex mice. 
PDGFR-α  and  PDGFR-β  are  receptor  tyrosine  kinases  highly  implicated  in  tumor 
development and metastasis. They have been implicated in lymphangiogenesis, alteration 
in tumor vasculature and interactions between metastatic microenviroment and malignant 
cells (Oestman et al.,  2007). In a recent study Rikova and colleagues identified PDGFR-α 
to  be  highly  activated in  NSCLC  (Rikova et  al.,  2007).  The group of  C.  Blobel  could 
demonstrate  that  activation  of  the  PDGFR-β  induced  ADAM17  activity  and  increased 
shedding of TNF-α and TGF-α from the cell surface (Mendelson et al., 2010). 
Axl belongs to the TAM family (Tyro3, Axl and Mertk) of receptor tyrosine kinases. It is a 
transmembrane protein, which is activated upon interaction with its ligand - growth arrest-
specific protein 6 (Gas6). It regulates cell survival, growth and migration thus influencing 
tumorigenesis  (Linger  et  al.,  2008).  Interestingly,  Axl  can  influence  proliferation  via 
activation of Ras/MAPK pathway upon Gas6 stimulation (Fridell et al., 1996) or expression 
of anti-apoptotic factors Bcl-XL and Bcl-2 via NF-κB activation (Demarchi et al.,  2001). 
Namely,  Gas6  stimulation  can  increase  IkB  degradation,  thus  releasing  NF-kB  and 
allowing its translocation to the nucleus where it act as a transcription factor. Increase of 
Axl  activity  and  its  over-expression  is  common  in  many  pathological  conditions, 
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mainly in cancer (Linger et al., 2010). Inhibition of Axl signaling downregulates expression 
of pro-inflammatory cytokines, which are important mediators of tumor metastasis (Holland 
et al., 2010).
Taking into consideration that tumors of ADAM17wt/wt mice have sustained inflammatory 
status which is reflected in TNF-α production and NF-κB activation, we can hypothesize 
that synergistic effect of Axl and TNF-α in activation of NF-κB in tumors of ADAM17wt/wt 
mice can lead to stronger inflammatory stimuli,  thus to increased infiltration of myeloid 
cells and poor prognosis.
A strong correlation between high EGFR activity and high ADAM17 levels in breast tumors 
was reported (Borrell-Pages et al., 2003). Interestingly, we did not see expected significant 
difference  in  phosphorylation  of  EGFR  between  ADAM17wt/wt and  ADAM17ex/ex mice. 
However, we could notice a slight difference in phosphorylation of ErbB3 and ErbB4 in 
tumor lysates of 3 weeks injected mice by Phospho-RTK antibody array.
Performing quantitative real time PCR, we were able to show that target genes of Notch 
signaling, Hes 1 and Hey 1, were upregulated in the whole lung tissue as early as 20h post 
LLC injection, peaking 7 days and at later time points decreasing to a basal level. We 
noticed a significant difference in the expression of these genes in tumor bearing lungs 
between  ADAM17wt/wt and  ADAM17ex/ex  animals.  Hypomorphic  mice  displayed  an 
upregulation of transcription of Notch target genes only at the earliest time point, and just 2 
times higher then the basal level with relapse to normal at later time points. Control mice 
had 3-4 times higher expression of both genes compared to untreated mice (basal level) 
20h after LLC inoculation. Maximum of the Hes 1 and Hey 1 expression was measured  7  
days  post  injection  with  relapse  to  basal  level  at  later  time  points.  This  implied  that 
ADAM17 was implicated in Notch activation shortly after tumor cell injection. We  assume 
that Notch is activated within the cancer cells. Because of the lack of ADAM17 activity in 
hypomorphic mice, endothelial  cells might be incapable to release a soluble Jagged-1, 
therefore impairing cancer stem cell formation. However, analysis of cancer stem cells in 
our model is still ongoing.
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It is known that Notch signaling has a multiple role in lung development, repair and cancer.
Notch  promotes  proximal  cell  fate  in  early  lung  development,  it  coordinates  alveolar 
formation via cell fate specification and cell differentiation in the parenchyma and vascular 
compartments. Knock-out studies for Notch-1, Notch-2, and the Notch ligands Jagged-1 
and  DLL-1  clearly  demonstrate  how  important  Notch  signaling  is  for  embryonic 
development, since these mutants die in an early embryonic stage. During development 
and progression of lung cancer, Notch signaling has a prominent role. In 30% of human 
lung cancers expression of the Notch inhibitor Numb is reduced, which was linked to a 
poor prognosis  (Westhoff  et al.,  2009).  Also,  Notch receptor signaling was analyzed in 
different lung cancer cell lines under hypoxic conditions, thus mimicking the surrounding in 
tumors. It was found that Notch-1 signaling was increased under hypoxic conditions and 
that  it  was  imperative  for  cancer  cell  survival  (Chen et  al.,  2007).  Interestingly,  under 
conditions  of  severe  hypoxia,  ADAM17  expression  and  activation  was  upregulated 
(Ryzmski et al., 2012). Ryzmski and colleagues could demonstrate that hypoxia inducible 
factor-1 alpha (HIF-1α) was important to maintain basal levels of ADAM17 mRNA under 
hypoxic conditions. Additionally, proteolytic release of Jagged-1 from endothelial cells by 
ADAM17 has been shown to be important for the transformation of colorectal cancer cells 
into cancer stem cells (Lu et al., 2013). Collectively, these findings point out the complexity  
and significance of Notch signaling, both for the host and for cancer cells, and the possible 
implication of ADAM17 in Notch activation.
Interestingly, in some cases activation of NF-κB signaling can support proliferatory signals. 
Therefore, we tested the influence of TNF-α on proliferation of LLC cells. Wild type LLC 
cells were treated for 144h with different concentrations of rm TNF-α.  24h after TNF-α 
stimulation,  all  stimulated  LLC  cells  had  a  significantly  higher  proliferation  rate  than 
unstimulated cells. 48h after TNF-α stimulation, there was no difference in the proliferation 
rate between TNF-α stimulated and unstimulated LLC cells. 
From these data we can conclude that TNF-α can be a proliferatory stimulus for cancer 
cells at very early stages of metastasis.
5.4  IL-6  trans-signaling  does  not  play  a  protective  role  in  LLC  induced  lung 
metastasis
In  previous  publications  IL-6  classic  and  trans-signaling  have  been  correlated  with 
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tumorigenesis (Bollrath et al., 2009).  Elevated level of IL-6 in patients suffering from lung 
and  breast  cancer,  was  strongly  correlated  with  a  poor  prognosis  (Qu  et  al.,  2009). 
Interestingly,  patients who suffer  from severe acute pancreatits  (SAP) as a secondary 
effect of disease develop acute lung injury (ALI) which much resembles the inflammatory 
state  in  lung  cancer.  Zhang  and  colleagues,  using  sgp130Fc  transgenic  mice,  could 
determine the underlying molecular mechanism in ALI development (Zhang et al., 2013).  
They demonstrated that blocking IL-6 trans-signaling increased survival rate via reduction 
of ALI in a mouse model of SAP. Using IL-6-/- mice, in a situation where IL-6 signaling is 
completely blocked, progression of disease was even enhanced. These data suggested 
that protective signals derive from classic IL-6 pathway, while disease stimulatory signals 
derived from IL-6 trans-signaling.  
Using sgp130Fc mice in our model of experimental metastasis with LLC cells we were 
able to show that blocking IL-6 trans-signaling did not have a beneficial effect on tumor 
metastasis. Both mice groups displayed same the tumor development and lung damage. 
Total lung weight was increased 3 times more than normal in both mice groups compared 
to untreated mice. We were able to detect one liver metastasis in sgp130Fc mice and none 
in control mice. Immunohistological analysis revealed the same immune response in the 
lungs of sgp130Fc mice like in C57Bl6/N control mice. Tumor bearing lungs of sgp130Fc 
mice displayed strong infiltration of Ly6G/Gr1+ cells but not of F4/80+ cells.
5.5 ADAM17 in tumor cells is necessary for tumor cell growth in vitro and in vivo
In order to investigate the importance of ADAM17 in tumor cells for tumor cell growth in 
vitro and in vivo, we generated LLC cells with stable ADAM17 knock down (kdADAM17-
LLC).  We  were  able  to  demonstrate  that  proliferation  of  kdADAM17-LLC  cells  was 
significantly reduced already in the first 24h. As compared to wtLLC cells, we observed 
that the difference in proliferation rate was increasing with time progression.
In preliminary experiments, we could see that lack of ADAM17 in tumor cells influences 
tumor growth  in vivo. We performed i.v. injection of kdADAM17-LLC cells into C57Bl6/N 
mice. We were able to see that lack of ADAM17 in the tumor cells resulted in null tumor 
formation in the lungs. 21 days after kdADAM17-LLC cell inoculation there were no visible 
tumors  in  the  lungs,  compared  to  control  mice  injected  with  wild  type  LLC  cells.  To 
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investigate the presence of kdADAM17-LLC cells in the lungs of injected mice, we isolated 
RNA from  the  whole  lung  tissue, and  performed  semiquantitative  RT-PCR  for  gene 
expression of mCherry. Confirming the expression of mCherry in the lungs of kdADAM17-
LLC injected mice, we were able to confirm the presence of kdADAM17-LLC cells in the 
whole lung tissue.
Our data demonstrate that  expression and activity  of  ADAM17 in the metastatic  niche 
significantly contributes to the growth of metastatic tumors. Targeting ADAM17 in the tumor 
stroma seem to be very promising as the tumor stroma is not prone to mutations (Junttila 
et al., 2013).
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6 Summary 
Most cancer deaths are not the result of primary cancer development, but rather the result 
of its spread, a process called metastasis. Metastasis is a complex process where cancer 
cells leave the original tumor site, intravasate into the bloodstream, migrate to a distant 
organs  and  initiate  invasive  growth.  Numerous  studies  have  contributed  to  better 
understanding the underlying cellular and molecular processes of metastasis.
In the present study we could show that ADAM17 plays a crucial role in the tumor cell  
growth in the metastatic niche of lung metastasis.
In a murine metastasis model using the LLC and B16F1 tumor cell lines we could see that 
ADAM17ex/ex animals,  that  express low levels  of  ADAM17,  had a much reduced tumor 
burden.  The reduced metastatic  growth  was  accompanied with  reduced expression  of 
inflammatory chemokines like e.g. MCP-1 and MIP-2.
Consequently,  we  observed  a  reduced  infiltration  of  inflammatory  cells,  in  particular 
Ly6G/Gr1+CD11b+ myeloid derived suppressor cells in ADAM17ex/ex mice.
Furthermore, ADAM17 seems to influence metastatic growth through the activation of the 
receptor  tyrosine  kinases  PDGFR-α and  Axl,  as  well  as  the  activation  of  the 
transmembrane protein Notch.
Taken  together,  ADAM17  represents  a  promising  drug  target  for  the  inhibition  of 
metastasizing process.
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6 Zusammenfassung
Mortalität bei Tumorerkrankungen ist meistens nicht auf das Wachstum des Primärtumors 
zurückzuführen,  sondern  vielmehr  auf  seine  maligne  Streuung,  der  Metastasierung. 
Metastasierung  ist  ein  komplexer  Prozess,  bei  dem  Tumorzellen  den  Primärtumor 
verlassen, in die Blutzirkulation eintreten, zu entfernten Organen wandern und dort invasiv 
wachsen.  Zahlreiche  Studien  haben  bereits  dazu  beigetragen,  die  zugrundeliegenden 
zellulären und molekularen Prozesse besser zu verstehen und dem Schritt einer kausalen 
Therapie metastasierender Erkrankungen näher zu kommen.
In  der  vorliegenden  Studie  können  wir  zeigen,  dass  ADAM17  in  metastasiernden 
Tumorzellen,  aber  vor  allem auch in  Zellen der  Metastasennische eine unverzichtbare 
Rolle für das Wachstum von Lungenmetastasen spielt. 
In  einem  tierexperimentellen  Metastasierungsmodell  mit  murinen  LLC  und  B16F1 
Tumorzellen konnten wir sehen, dass ADAM17ex/ex Mäuse, die nahezu kein ADAM17 mehr 
exprimieren,  eine  deutlich  reduzierte  Tumorlast  aufwiesen.  Das  reduzierte 
Metastasenwachstum  ging  einher  mit  einer  verminderten  Expression  entzündlicher 
Zytokine,  wie  TNFa  und  IL1b  und  einer  verminderten  Expression  an  enzündlichen 
Chemokinen wie z.B. MCP-1 und MIP-2. Als Resultat konnten wir in ADAM17ex/ex Tieren 
eine  reduzierte  Infiltration  entzündlicher  Zellen,  insbesondere  sg.  Ly6G/Gr1+CD11b+ 
myeloider Immunsupressorzellen feststellen. 
ADAM17  scheint  darüberhinaus  das  Metastasenwachstum  durch  die  Aktivierung  der 
Rezeptortyrosinkinasen  PDGFR-α und  Axl,  sowie  dem  Transmembranprotein  Notch 
maßgeblich zu beeinflussen.
Zusammengefasst stellt  ADAM17 ein vielversprechendes drug target  für  die  Hemmung 
metastasierender Prozesse dar.
81
References                                                              
 
7 References
                         
Albina, J.E.,  M. Caldwell,  W.L. Henry and C.D. Mills.  1989. Regulation of macrophage 
function by L-arginine. J. Exp. Med. 169, 1021-1029.
         
Baud, V. and Karin, M. 2009. Is NF-κB good target for cancer therapy? Hopes and pitfalls. 
Nat. Rev. Drug Discovery 8, 33-40.
Baumgart, A., S. Seidl, P. Vlachou, L. Michel, N. Mitova, N. Schatz, K. Specht, I. Koch, T. 
Schuster, R. Grundler, M. Kremer, F. Fend, J.T. Siveke, C. , Peschel, J. Duyster and T.  
Dechow. 2010. ADAM17 regulates Epidermal Growth Factor Receptor expression through 
the activation of Notch1 in Non–small cell lung cancer. Cancer Res. 70, 5368-5378.
Becker, C., M.C. Fantini, C. Schramm, H.A. Lehr, S. Wirtz, A. Nikolaev, J. Burg, S. Strand, 
R. Kiesslich,  S, Huber,  H. Ito,  N. Nishimoto,  K. Yoshizaki, T.  Kishimoto, P.R. Galle,  M. 
Blessing, S. Rose-John and M.F. Neurath. 2004. TGF-beta suppreses tumor progression 
in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21, 491-501.
Belperio, J.A., M.P. Keane, M.D. Burdick,V. Londhe, Y.Y. Xue, K. Li, R.J. Phillips and R.M. 
Strieter.  2002. Critical  role  for CXCR2 and CXCR2 ligands during the pathogenesis of  
ventilation-induced lung injury. J. Clin. Invest. 110, 1703-1716. 
          
Black, R. A., and J. M. White. 1998. ADAMs: focus on the protease domain. Curr. Opin.  
Cell Biol. 10, 654-659.
Blanschot-Jossic, F., A. Jarry, D. Masson, K., Bach-Ngohou, J. Paineau, M.G. Denis, C.L. 
Laboisse and J.F. Mosnier. 2005. Up-regulated expression of ADAM17 in human colon 
carcinoma: co-expression with EGFR in neoplastic and endothelial cells.  J. Pathol.  207, 
156-163.
Blobel, C. P. 1997. Metalloprotease-disintegrins: links to cell  adhesion and cleavage of  
TNF alpha and Notch. Cell 90, 589-592.
82
References                                                              
Borrell-Pages, M., F. Rojo, J. Albanell, J. Baselga and J. Arribas. 2003. TACE is required 
for the activation of the EGFR by TGF-α in tumors. EMBO J. 22, 1114-1124.
            
Bollrath,  J.,  T.J.  Phesse,  V.A.  Von Burstin,  T.  Putoczki,  M.  Bennecke,  T.  Bateman,  T. 
Nebelsiek,  T.  Lundgren-May,  O.  Canli,  S.  Schwitalla,  V.  Matthewa,  R.M.  Schmid,  T. 
Kirchner, M.C. Arkan, M. Ernst and F.R. Greten. 2009. gp130-mediated Stat3 activation in 
enterocytes  regulates  cell  survival  and  cell-cycle  progression  during  colitis-associated 
tumorigenesis. Cancer Cell 15, 91–102.
Nijkamp,  F.P.  And  M.J.  Parnham.  Principles  of  Immunopharmacology:  3 rd revised  and 
extended edition. 10.1007/978-3-0346-0136-8_2. Springer, Basel, 2011. 
Brou, C., F. Logeat, N. Gupta, C. Bessia, O. LeBail, J.R. Doedens, A. Cumano, P. Roux, 
R.A. Black and A. Israeal. 2000. A novel proteolytic cleavage involved in Notch  Signaling: 
The role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216.
Bozkulak,  E.  and  Weinmaster,  G.  2009.  Selective  use  of  ADAM10  and  ADAM17  in 
activation of Notch1 signaling. Mol. Cell. Biol. 29, 5679-5695.
Carswell,  E.A.,  L.J.  Old, R.L. Kassel,  S. Green, N. Fiore and B.  Williamson. 1975. An 
endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. 72, 
3666–3670.
Catlett-Falcone, R., T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. 
Ciliberto, L. Moscinski, J.L. Fernandez-Luna, G. Nunez, W.S. Dalton and R. Jove. 1999. 
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 
myeloma cells. Immunity 10, 105-115.
Chalaris,  A.,  N.  Adam,  C.  Sina,  P.  Rosenstiel,  J.  Lehmann-Koch,  P.  Schirmacher,  D. 
Hartmann, J.  Cichy, O. Gavrilova, S. Schreiber,  T. Josrock,  V. Matthews, R. Häsler,  C. 
Becker,  M.F.  Neurath,  K. Reiss, P. Saftig,  J.  Scheller and S. Rose-John.  2010. Critical 
roleof the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration 
in mice. J. Exp. Med. 207, 1617-1624.
83
References                                                              
Chen, Y., M.A. De Marco, I. Graziani, A.F. Gazdar, P.R. Strack, L. Miele and M. Bocchetta.  
2007.  Oxygen concentration determines the biological  effects  of  NOTCH-1 signaling in 
adenocarcinoma of the lung. Cancer Res. 67, 7954-7959.
Demarchi, F., R. Verardo, B. Varnum, C. Brancolini and C. Schneider. 2001. Gas6 anti-
apoptotic signaling requires NF-κB activation. J. Biol. Chem. 276, 31738-31744.
Diep, B.A., L. Chan, P. Tattevin, O. Kajikawa, T.R. Martin, L. Basuino, T.T Mai, H. Marbach, 
K. Braughton, A.R. Whitney, D.J. Gardner, X. Fan, C.W. Tseng, G.Y. Liu, C. Badiou, J.  
Etienne, G. Lina, M.A. Matthay, F.R. DeLeo and H.F. Chambers. 2010. Polymorphonuclear 
leukocytes  mediate  Staphylococcus  aureus Panton-Valentine  leukocidin-induced  lung 
inflammation and injury. Proc. Natl. Acad. Sci. 12, 5587–5592.
Ding,  X.,  L.Y.  Yang,  G.W.  Huang,  W.  Wang  and  W.Q.  Lu.  2004.  ADAM17  mRNA 
expression and pathological features of hepatocellular carcinoma. World J. Gastroenterol. 
10, 2735-2739.
Dreymueller, D., C. Martin, T. Kogel, J. Pruessmeyer, F.M. Hess, K. Horiuchi, S. Uhlig and 
A. Ludwig. 2012. Lung endothelial ADAM17 regulates the acute inflammatory response to 
lipopolysaccharide. EMBO Mol. Med. 4, 412-423.
 
Fridell, Y.W.C., Y. Jin, L.A. Quilliam, A. Burchert, P. McCloskey, G. Spizz, B. Varnum, C. 
Der  and  E.T.  Liu.  1996.  Differential  activation  of  the  Ras/extracellular-signal-regulated 
protein kinase pathway is responsible for the biological consequences induced by the Axl 
receptor tyrosine kinase. Mol. Cell. Biol. 16, 135-145.
Fidler, I. J. 2003. The pathogenesis of cancer metastasis: the „seed and soil“ hypothesis 
revisited. Nat. Rev. Cancer 3, 453-458.
Fu, S., N. Zhang, A.C. Yopp, D. Chen, M. Mao, D. Chen, H. Zhang, Y. Ding and J.S.  
Bromberg. 2004. TGF-β induces Focp3+ T-regulatory cells from CD4+CD25 precursors. 
Am. J. Transplant. 4, 1614-1627.
84
References                                                              
Gabrilovich, D.  and  Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of 
the immune system. Nature 9, 162-174.
Grell, M., E. Douni, H. Wajant, M. Loehden, M. Clauss, B. Mazeiner, S. Georgopoulos, W. 
Lesslauer, G. Kollias, K. Pfizenmaier and P. Scheurich. (1995). The transmembrane form 
of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor  
receptor. Cell 83, 793–802.
Greten, T.F., M.P. Manns and F. Korangy. 2011. Myeloid derived suppressor cells in human 
diseases. Int. Immunopharmacol. 11, 802-807.
Gupta, S., L. Feng, T. Yoshimura, J. Redick, S.M. Fu and C.E.Jr. Rose. 2006. Intra-alveolar 
macrophage-inflammatory peptide 2 induces rapid neutrophil localization in the lung. Am. 
J. Respir. Cell. Mol. Biol. 15, 656-63.
Hanahan, D. and Weinberg, R.A. 2000. The  hallmarks of Cancer. Cell 100, 57-70. 
Hanahan, D. and Weinberg, R.A. 2011. Hallmarks of Cancer: The Next Generation.  Cell 
144, 646-674.
Hanson,  E.M.,  V.K.  Clements,  P. Sinha,  D.  Ilkovitch and S.  Ostrand-Rosenberg.  2009. 
Myeloid-derived  suppressor  cells  down-regulate  L-selectin  expression  on  CD4+ and 
CD8+ T cells. J. Immunol. 183, 937-944.
Harrari, O. and J.L. Liao. 2004. Inhibition of MHC II gene transcription by nitric oxide and 
antioxidants. Curr. Pharm. Des. 10, 893-898.
Holland, S.J., A. Pan, C. Franci, Y. Hu, B. Chang, W. Li, M. Duan, A. Torneros, J. Yu, T.J.  
Heckrodt, J. Zhang, P. Ding, A. Apatira, J. Chua, R. Brandt, P. Pine, D. Goff, R. Singh, D.G. 
Payan and Y. Hitoshi. 2010. R428, a selective small molecule inhibitor of Axl kinase, blocks 
tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 
1544–1554. 
85
References                                                              
Huang, B., P.-J. Pan, Q. Li, A.I. Sato, D.E. Levy, J.Bromberg, C.M. Divino and S.-H. Chen. 
2006. Gr1+CD115+ Immature myeloid suppressor cells mediate the development of tumor-
induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66, 1123-
1131.
Huang, B., Z. Lei, J. Zhao, W. Gong, J. Liu, Z. Chen, Y. Liu, D. Li, Y. Yuan, G.M. Zhang, 
and Z.H. Feng. 2007. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor 
cells to cancers. Cancer Lett. 252, 86-92.
Huang M.T., Y.S. Dai, Y.B. Chou, Y.H. Juan, C.C Wang and B.L. Chiang. 2009. Regulatory 
T-cells negatively regulate  neovasculature of airway remodeling via DLL4-Notch signaling. 
J. Immunol. 183, 4745-4754.
Isogai, Z., T. Shinomura, N. Yamakawa, J. Takeuchi, T. Tsuji, D. Heinegard and K. Kimata. 
1996.  2B1  antigen  characteristically  expressed  on  extracellular  matrices  of  human 
malignant tumors is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res. 
56, 3902-3908.
Jinushi,  M.,  H.  Yagita,  H.  Yoshiyama  and  H.  Tahara.  2013.  Putting  the  brakes  on 
anticancer  therapies:  suppression  of  innate  immune  pathways  by  tumor-associated 
myeloid cells. Trends Mol. Med. 19, 536-545.
Jostock, T., J. Muellberg, S. Ozbek, R. Atreya, G. Blinn, N. Volyz, M. Fischer, M.F. Neurath 
and S. Rose-John. 2001.  Soluble gp130 is the natural  inhibitor  of  soluble interleukin-6 
receptor transsignaling responses. Eur. J. Biochem. 268, 160-167.
Joyce,  J.A.  and Pollard,  J.W.  2009.  Microenvironmental  regulation  of  metastasis.  Nat.  
Rev. Cancer  9, 239-52.
Junttila,  M.R.  and  de  Sauvage,  F.  2013.  Influence  of  tumor  microenvironment 
heterogeneity in therapeutic response. Nature 501, 346-354.
Kaplan, R.N., R.D. Riba, S. Zacharoulis, A.H. Bramley, L. Vincent, C. Costa, D.D. Mac 
86
References                                                              
Donald, D.K. Jin, K. Shido, S.A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J.L. Port, N.  Altorki, E.R. 
Port, D. Ruggero, S.V. Shmelkov, K.K. Jensan, S. Rafii and D. Lyden. 2005. VEGFR1-
positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 
438, 820-827.
Kawai, T. and Akira, S. 2007. Signaling to NF-κB by Toll-like receptors. Trends Mol. Med. 
13, 460-469.
Kim, S., H. Takahashi, W.W. Lin, P. Descargues, S. Grivennikov, Y. Kim, J.L. Luo and M. 
Karin. 2009. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate 
metastasis. Nature 457, 102-107.
Kishimoto, T., S. Akira, M. Narazaki, and T. Taga. 1995. Interleukin-6 family of cytokines 
and gp130. Blood 86, 1243-1254.
Kopan, M. and M.X.G. Liagan. 2009. The Canonical Notch Signaling Pathway: Unfolding 
the Activation Mechanism. Cell 137, 216-233.
Kusmartsev. S., Y. Nefedova, D. Yoder and D. Gabrilovich. 2004. Antigen-specific inhibition 
of CD8+ T cell  response by immature myeloid cells in cancer  is mediated by reactive 
oxygen species. J. Immunol. 172, 989-999.
Linger,  R.M.,  A.K.  Keating,  H.S.  Earp and D.K.  Graham.  2008.  TAM receptor  tyrosine 
kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. 
Adv. Cancer Res. 100, 35–83.
Linger, R.M., A.K. Keating, H.S. Earp and D.K. Graham. 2010. Taking aim at Mer and Axl 
receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin. Ther.  
Targets 14, 1073–1090.
Lu, J., X. Ye, F. Fan, L. Xia, R. Bhattacharya, S. Bellister, F. Tozzi, E. Sceusi, Y. Zhou, I.  
Tachibana, D.M. Maru, D.H. Hawke, J. Rak, S.A. Mani, P. Zweidler-McKay and L.M. Ellis.  
2013.  Endothelial  cells promote the Colorectal  Cancer  Stem Cell  phenotype through a 
soluble form of Jagged-1. Cancer Cell 23, 171-185.
87
References                                                              
Ludwig, A., C. Hundhausen, M. H. Lambert, N. Broadway, R. C. Andrews, D. M. Bickett, M.  
A. Leesnitzer, and J. D. Becherer. 2005. Metalloproteinase inhibitors for the disintegrin-like 
metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol 
ester-inducible shedding of cell surface molecules. Comb. Chem. High Throughput Screen  
8, 161-171.
Luo, J.L., S. Maeda, L.C. Hsu, H. Yagita and M. Karin. 2004. Inhibition of NF-kB in cancer 
cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated 
tumor regression. Cancer Cell 6, 297-305.
Mackay, H.J. and Twelves, C.J. 2007. Targeting the protein kinase C family: are we there 
yet? Nat. Rev. Cancer  7, 554-562.
Männel, D.N., P. Orosz, M. Hafner and W. Falk. 1994. Mechanisms involved in metastasis 
enhanced by inflammatory mediators. Circ. Shock. 44, 9-13.
Matthews,  V.,  B.  Schuster,  S.  Schütze,  I.  Bussmeyer,  A.  Ludwig,  C.  Hundhausen,  T. 
Sadowski,  P.  Saftig,  D.  Hartmann,  K.  J.  Kallen,  and  S.  Rose-John.  2003.  Cholesterol 
depletion of the plasma membrane triggers shedding of the human interleukin-6 receptor 
by TACE and independently of PKC. J. Biol. Chem. 278, 38829- 38839.
Mendelson, K., S. Swendeman, P. Saftig and C.P. Blobel. 2010. Stimulation of Platelet-
derived  Growth  Factor  Receptor  (PDGFR)  Activates  ADAM17  and  Promotes 
Metalloproteinase-dependent  cross-talk  between  the  PDGFR  and  Epidermal  Growth 
Factor Receptor (EGFR) signaling pathways. J. Biol. Chem. 285, 25024-25032.
Minn, A.J., G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, A. Vial, A., Olshen, W.L. 
Gerald and J.  Massague. 2005. Genes that mediate breast cancer metastasis to lung. 
Nature 436, 518-524.
Monter-Julian, F.A. 2001. The soluble IL-6 receptors: serum levels and biological function. 
Cell Mol. Biol. (Noisy-le-grand) 47, 583-597.
88
References                                                              
Movahedi,  K.,  M.  Guilliams,  J.  Van  den  Bossche,  C.  Gysemans,  A.  Beschin,  P.  De 
Baetselier  and  J.A.  Van  Ginderachter.  2008.  Identification  of  a  discrete  tumor-induced 
myeloid-derived suppressor  cell  subpopulations with  distinct  T-cell  suppressive activity. 
Blood 111, 4233-4244.
Mueller-Newen, G.A., A. Kuster, U. Hammann, R. Kuel, U. Horsten, A. Martens, L. Graeve,  
J. Wijdenes and P.C. Heinrich. 1998. Soluble IL-6 receptor potentiates the antagonistic 
activity of soluble gp130 on IL-6 responses. J. Immunol. 161, 6347-6355.
Muraguchi,  A.,  T.  Hirano, B. Tang, T. Matsuda, Y. Horii,  K. Nakajima and T. Kishimoto. 
1988.  The  essential  role  of  B  cell  stimulatory  factor  2  (BSF-2/IL-6)  for  the  terminal 
differentiation of B cells. J. Exp. Med. 167, 332-344.
Ni,  S.S.,  J.  Zhang,  W.L.  Zhao,  X.C.  Dong  and  J.L.  Wang.  2013.  ADAM17  is  over-
expressed in Non-small cell lung cancer and its expression correlates with poor patient 
survival. Tumor Biol. 34, 1813-1818.
Olayioye, M.A., RM. Neve, H.A. Lane and N.E. Hynes. 2000. The erbB signaling network: 
heterodimerization in development and cancer. EMBO J. 19, 3159-3167.
Palladino,  M.A.,  F.R.  Bahjat,  E.A.  Theodorakis  and  L.L.  Moldawer.  2003.  Anti-TNF-α 
therapies: the next generation. Nat. Rev. Drug Discov. 2, 736-746.
Pannuti,  A.,  K.  Foreman, P.  Rizzo,  C.  Osipo,  T.  Golde,  B.  Osborn and l.  Miele.  2010. 
Targeting Notch to target cancer stem cells. Clin. Cancer Res. 16, 3141-3152.
Peschon,  J.J.,  J.L.  Slack,  P.,  Reddy,  K.L.  Stocking,  S.W.  Sunnarborg,  D.C.  Lee,  W.E. 
Russell, B.J. Castner, R.S. Johnson, J.N. Fitzner, R.W. Boyce, N. Nelson, C.J. Kozlosky, 
M.F. Wolfson, C.T. Rauch, D.P. Cerretti, R.J. Paxton, C.J. March and R.A. Black. 1998. An 
essential role for ectodomain shedding in mammalian development.  Science 282, 1281-
1284.
Pirinen, R., T. Leinonen, J. Boehm, R. Johansson, K. Ropponen, E. Kumpulainen and V.M. 
89
References                                                              
Kosma.  2005.  Versican  in  non-small  cell  lung  cancer:  relation  to  hyaluronan, 
clinicopathologic factors, and prognosis. Hum. Pathol. 36, 44-50.
Rabe, B.,  A.Chalaris, U. May, G.H. Waetzig,  D. Seegert,  A.S. Williams, S.A. Jones, S. 
Rose-John  and  J.  Scheller.  2008.  Transgenic  blockade  of  interleukin  6  transsignaling 
abrogates inflammation. Blood 111, 1021-1028.
Ranganathan, P., K.L. Weaver and A.J. Capobianco. 2011. Notch signaling in solid tumors: 
a little bit of everything but not all the time. Nature 11, 338-351.
Richards,  F.M.,  C.J.  Tape,  D.I.  Jodrell  and  G.  Murphy.  2012.  Anti-tumour  effects  of  a 
specific anti-ADAM17 antibody in an ovarian cancer model in vivo. PLoS One 7, 1-10.
Rikova, K.,  A.  Gua,  Q.  Zeng, A. Possemato, J.  Yu,  H. Haack,  J.  Nardone,  K. Lee, C. 
Reeves, Y. Li, Y. Hu, Z. Tan, M. Stokes, L. Sullivan, J. Mitchell, R. Wetzel, J. Macneill, J.M. 
Ren, J. Yuan, C.E. Bakalarski, J. Villen, J.M. Kornhauser, B. Smith, D. Li, X. Zhou, S.P. 
Gygi,  T.L.  Gu,  R.D.  Polakiewicz,  J.  Rush  and  M.J.  Comb.  2007.  Global  survey  of 
phosphotyrosine signaling identifies oncogenic kinases in lung cancer.  Cell 131,  1190-
11203.
Rivas, M.A., R.P. Carnevale, C.J. Proietti, C. Rosemblit,  W. Beguelin, M. Salatino, E.H. 
Charreau, I. Frahm, S. Sapia, P. Brouckaert, P.V. Elizalde and R. Schillaci. 2008.  TNFα 
acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-
dependent pathways. Exp. Cell Res. 314, 509-519.
Rivoltini, L., M. Carrabba, V. Huber, C. Castelli, L. Novellino, P. Dalebra, R. Mortarini, G.  
Arancia, A. Anichini, S. Fais and G. Parmiani. 2002. Immunity to cancer: attack and escape 
in T-lymphocyte-tumor cell interaction. Immunol. Rev. 188, 97-113.
Rodriguez, P.C.  A.R. Zea, K.S. Culotta, J. Zabaleta, J.B. Ochoa and A.C.Ochoa. 2002. 
Regulation of T-cell  receptor CD3ζ chain expression by L-arginine. J. Biol.  Chem. 277, 
21123-21129.
90
References                                                              
Rodriguez, P.C., D.G. Quiceno and A.C. Ochoa. 2007. L-arginine availability regulates T-
lymphocyte cell-cycle progression. Blood 109, 1568-1573.
Romashkova, J.A. and Makarov, S.S. 1999. NF-kappaB is a target of AKT in anti-apoptotic 
PDGF signalling. Nature 401, 89-90.
Rose-John, S. 2012.  IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for 
the Pro-Inflammatory Activities of IL-6. Int. J. Biol. Sci. 8, 1237-1247.
Rose-John,  S.,  Waetzig,  G.H.,  Scheller,  J.,  Groetzinger,  J.  and Seegert,  D.  2007.  The 
IL6/sIL-6R complex  as  a  novel  target  for  therapeutic  approaches.  Expert  Opin.  Ther.  
Targets 11, 613-624.
Ryzmski, T., A. Petry, D. Kracun, F. Reiss, L. Pike, A.L. Harris and A. Goerlach. 2012. The 
unfolded protein response controls induction and activation of ADAM17/TACE by severe 
hypoxia and ER stress. Oncogene 31, 3621-3634.
Sahin, U., G. Weskamp, K. Kelly, H.M. Zhou, S. Higashiyama, J. Peschon, D. Hartmann, 
P.  Saftig.  and  Blobel.  2004.  Distinct  roles  for  ADAM10  and  ADAM17  in  ectodomain 
shedding of six EGFR ligands. J. Cell Biol. 164, 769-779.
Santiago-Josefat,  B.,  C.  Esselens,  J.J.  Bech-Serra  and  J.  Arribas.  2007.  Post-
transcriptional  up-regulation  of  ADAM17  upon  Epidermal  Growth  Factor  Receptor 
activation and in breast tumors. J. Biol. Chem. 282, 8325-8331.
Sawanobori, Y.,  S. Ueha, M. Kurachi, T. Shimaoka, J.E. Talmadge, J. Abe, Y. Shono, M. 
Kitabatake, K. Kakimi, N. Mukaida and K. MatsushimA. 2008. Chemokine-mediated rapid 
turnover of myeloid-derived suppressor cells in tumor bearing mice. Blood 111, 5457-5466.
Scheller, J., A. Chalaris, C. Garbers and S. Rose-John. 2011. ADAM17-molecular switch to 
control inflammation and tissue regeneration. Trends Immunol. 32, 380-387.
Schloendorff,  J.,  J.D.  Becherer  and  C.P.  Blobel.  2000.  Intracellular  maturation  and 
91
References                                                              
localization of the tumor necrosis factor α convertase (TACE). Biochem. J. 347, 131-138.
Schmielau,  J.  and  O.J.  Finn.  2001.  Activated  granulocytes  and  granulocyte-derived 
hydrogen  peroxide  are  the  underlying  mechanism of  suppression  of  T-cell  function  in 
advanced cancer patients. Cancer Res. 61, 4756-4760.
Seo. N.,  S. Nayakawa, M. Takigawa and Y. Tokura. 2001. Interleukin-10 expression at  
early tumor sites induces subsequent generation of CD(4+) T-regulatory cells and systemic 
collapse of antitumor immunity. Immunology 103, 449-457.
Shackleton, M., E. Quintana, E.R. Fearon and S. Morrison. 2009. Heterogeneity in cancer: 
cancer stem cells versus clonal evolution. Cell 138, 822-829.
Smalley, D.M. And K. Ley. 2005. L-selectin: mechanisms and physiological significance of  
ectodomain cleavage. J. Cell. Mol. Med. 9, 255-266.
Soria,  G. and A. Ben-Baruch. 2008. The inflammatory chemokines CCL2 and CCL5 in 
breast cancer. Cancer Lett. 267, 271-285.
Srivastava, M.K., P. Sinha, V.K. Clements, P. Rodriguez and S. Ostrand-Rosenberg. 2010. 
Myeloid derived suppressor cells inhibit T-cell activation by depleting cystin and cystein.  
Cancer Res. 70, 68-77.
Stöcker, W., F. Grams, U. Baumann, P. Reinemer, F. X. Gomis-Ruth, D. B. McKay, and W. 
Bode.  1995.  The metzincins-topological  and sequential  relations between the astacins, 
adamalysins,  serralysins,  and  matrixins  (collagenases)  define  a  superfamily  of  zinc-
peptidases. Protein Sci. 4, 823-840.
Tabaries,  S.,  Z.  Dong,  M.G.  Annis,  A.  Omeroglu,  F.  Pepin,  V.  Ouellet,  C.  Russo,  M. 
Hassanain, P. Metrakos, Z. Diaz, M. Basik, N. Bertos, M. Park, C. Guettier, R. Aam, M. 
Hallett  and  P.M.  Siegel.  2011.  Claudin-2  is  selectively  enriched  in  and  promotes  the 
formation of breast cancer liver metastases through engagement of integrin complexes. 
Oncogene 30, 1318-28.
92
References                                                              
Tarin,  D.  2008.  Comparisons  of  metastases  in  different  organs:  biological  and  clinical  
implications. Clin. Cancer Res. 14, 1923-1925.
Valastyan,  S.  and  R.A.  Weinberg.  2011.  Tumor  metastasis:  Molecular  Insights  and 
Evolving Paradigms. Cell 147, 275-292.
Vickers,  S.M.,  L.A.  MacMillan-Crow,  M  Green,  C.  Ellis  and  J.A.  Thompson.  1999. 
Association  of  increased  immunostaining  for  inducible  nitric  oxide  synthase  and 
nitrotyrosine with fibroblast growth factor transformation in pancreatic cancer. Arch. Surg. 
134, 245-251.
Wanf, Y., A.C. Zhang, Z. Ni, A. Herrera and B. Walcheck. 2010. ADAM17 activity and other 
mechanisms  of  soluble  L-selectin  production  during  death  receptor-induced  leukocyte 
apoptosis. J. Immunol. 184, 444744-54.
Westhoff,  B.,  I.N.  Colaluca, G.  D'Ario,  M. Donzelli,  D. Tosoni,  S.  Volorio,  G. Pelosi,  L. 
Spaggiari, G. Mazzarol, G. Viele, S. Pece and P.P. Di Fiore. 2009. Alterations of the Notch 
pathway in lung cancer. Proc. Natl. Acad. Sci. 106, 22293-22298.
Waetzig, G.H. and Rose-John, S. 2012. Hitting a complex target: an update on interleukin-
6 trans-signalling. Expert Opin. Ther. Targets 16, 225-36.
Yan, H.H., M. Pickup, Y. Pang, A.E. Gorska, Z. Li, A. Chytil, Y. Geng, J.W. Gray, H.L. 
Moses  and  L.  Yang.  2010.  Gr1+CD11b+  Myeloid  cells  tip  the  balance  of  Immune 
protection tumor promotion in the premetastatic lung. Cancer Res. 70, 6139-6149.
Yi, H., H.J. Cho, S.M. Cho, K. Jo, J.A. Park, N.H. Kim, G.L. Amidon, J.S. Kim and H.C. 
Shin.2012. Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung 
cancer stem cells. Int. J. Oncol. 41, 310-316.
Young, J. I., S. Nagaraj, M. Collazo and D.I. Gabrilovich. 2008. Subsets of myeloid-derived 
suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802.
 
93
References                                                              
Zhang,  H.,  P. Neuhoefer,  L.  Song, B. Rabe,  M. Lesina,  M.U. Kurkowski,  M.  Treber,  T. 
Wartmann, S. Regner, H. Thorlacius, D. Saur, G. Weirich, A. Yashimura, W. Halangk, J.P. 
Mizgerd, R.M. Schmidt, S. Rose-John and H. Algül. 2013. IL-6 trans-signaling promotes 
pancreatitis associated lung injury and lethality. J. Clin. Invest. 123, 1019-1031.
Zhang, T., C.J. Guo, Y. Li, S.D. Douglas, X.X. Qi, L. Song and W.Z. Ho. 2003. Interleukin-
1beta induces macrophage inflammatory protein-1beta expression in human hepatocytes. 
Cell Immunol. 226, 45-53.
Zhou, B.B., M. Peyton, B. He, C. Liu, L. Girard, E. Caudler, Y. Lo, F. Baribaud, I. Mikami, N. 
Reguart, G. Yang, Y. Li, W. Yao, K. Vaddi, A.F. Gazdar, S.M. Friedman, D.M. Jablons, R.C.
Newton,  J.S.  Fridman,  J.D.  Minna  and  P.A.  Scherle.  2006.  Targeting  ADAM-mediated 
ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer 
Cell 10, 39-50.
Zwick, E., J. Bange and A. Ullrich. 2008. Receptor tyrosine kinase signaling as a target for  
cancer intervention strategies. Endocr. Relat. Cancer 8, 161-173.
94
Appendix                                                                
8 Abbreviations
ADAM17 A Disintegrin and Metalloprotease 17
AR Amphiregulin
APS Amonium- persulphat
B16F1 Murine melanoma cell line
BCD Blasticidin
BMDC Bone Marrow Derived Cells 
BMDM Bone Marrow Derived Macrophages
BMDN Bone Marrow Derived Neutrophils
BSA Bovine Serum Albumin
Br Bromine
bp base pair
OC degrees of Celsius
C5/C5a Complement component 5
CaCl2 Calcium (II) - chloride
(Ca)3(PO4)2 Calcium (II) - phosphate
CCL2 Chemokine (C-C motif) ligand 2
CCL3 Chemokine (C-C motif) ligand 3
CCL4 Chemokine (C-C motif) ligand 4
CCL5 Chemokine (C-C motif) ligand 5
CCL12 Chemokine (C-C motif) ligand 12
CD Cluster of Differentiation
CDK2 Cyclin-dependent kinase 2
Co-R Transcriptional co-repressors
CSF-1 Macrophage colony-stimulating factor 1
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CSF1R Macrophage colony-stimulating factor 1 Receptor
CSL DNA-binding protein
CXCR4 C-X-C chemokine receptor type 4
CXCL12 C-X-C motif chemokine 12 (also known as SDF-1)
CXCL1 C-X-C motif chemokine 1 (also known as KC)
CXCL2 C-X-C motif chemokine 2 (also known as MIP-2α)
CXCL8 C-X-C motif chemokine 8
CXCL9 C-X-C motif chemokine 9
CXCL10 C-X-C motif chemokine 10
DD Death Domain
ddH2O Double-distilled water
DMEM Dulbecco's Modified Eagle Medium
DNA Deoxyribonucleic Acid
dNTP Deoxy-nucleoside triphosphate
EDTA Ethylenediaminetetraacetic acid
EGF Epidermal Growth Factor 
EGFR Epidermal Growth Factor Receptor
ELISA Enzyme-Linked Immunosorbent Array
EMT Epithelial-Mesenchymale Transition
ER Endoplasmic Reticulum
Erk1/2 extracellular-signal-regulated kinases 1/2
FACS Fluorescence-activated cell sorting
FCS Fetal Calf Serum
FGFR 2 Fibroblast growth factor receptor 2
FGFR 3 Fibroblast growth factor receptor 3
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g gram
G-CSF Granulocyte Colony-stimulating Factor 
GI GI254023X – hydroxamate inhibitor of the ADAM10
Glc Glucose
Gln L-glutamine
gp130 Glycoprotein 130
Gr1 Granulocyte marker
GW GW280264X –  hydroxamate inhibitor of the ADAM17 and 
ADAM10
HB-EGF Heparin Binding – Epidermal Growth Factor 
HBS Hepes Buffered Saline
HE Hematoxylin/Eosine
HEK293T Human Embryonic Kidney 293 cells 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
Hes Hairy and enhancer of split-1
Hey Hairy/enhancer-of-split related with YRPW motif protein 1
HRP Horseradish-peroxidase
H2SO4 Sulfuric acid
ICAM-1 Intercellular Adhesion Molecule 1
IGF-1R Insulin-like growth factor 1 receptor
INF-γ Interferon gamma
IkB Inhibitor of NF-κB
IKK IκB kinase
IL-1β Interleukin 1 beta
IL-1R Interleukin 1 receptor
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IL-6 Interleukin 6
IL-6R Interleukin 6 Receptor
IL-8 Interleukin 8
IL-16 Interleukin 16
iNOS Inducible nitric oxide synthase
KCl Potassium (I) - Chloride
kDa kiloDalton
KHCO3 Potassium-hydrogen carbonate
L liter
LLC Lewis Lung Carcinoma 
LPS Lypopolisaccharide
MAM Mastermind - co-activator
MAPK Mitogen activated protein kinase
MCP-1 Monocyte chemotactic protein-1
M-CSF Macrophage-Colony stimulating factor 
MDSC Myelod Derived Suppressor Cells 
MEM Minimum Essential Medium
MEKK 1 Mitogen-activated protein kinase kinase kinase 1
min minute
MIP-1β Macrophage Inflammatory protein – 1 beta
MIP-2 Macrophage Inflammatory protein - 2
mg milligram
ml milliliter
mM millimolar
µl microliter
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μM micromolar
MMP2 Matrix metalloprotease 2
MMP9 Matrix metalloprotease 9
mRNA Messenger Ribonucleic acid
MSPR Macrophage-stimulating protein receptor
MuSK Muscle-Specific Kinase
NaCl Sodium Chloride
NaF Sodium Fluoride
Na2HPO4 Sodium hydrogenphosphate
Na2HPO4x2H2O Sodium hydrogenphosphate dihydrate
Na3VO4 Sodium vanadate
NH4Cl Amonium chloride
NF-κB Nuclear Factor kappa B
NICD Notch intracellular domain
NIK NF-κB-inducing kinase
ng nanogram
NO Nitric-oxide
NK Natural killer cell 
NP-40 Nonyl phenoxypolyethoxylethanol
NSCLC Non-small cell lung cancer 
ONOO- Peroxynitrite
PBS Phosphate buffered saline
PCNA Proliferating Cell Nuclear Antigen 
PDGF Platelet-derived growth factor
PDGFRα Platelet-derived growth factor receptor alpha
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PDGFRβ Platelet-derived growth factor receptor beta
P-Erk1/2 Phosphorylated extracellular-signal-regulated kinases
P-IKK Phosphorylated IκB kinase
PI-3-K Phosphatydil inositol – 3 kinase
PKC Protein kinase C
PMN Polumorphonuclear cell
PMSF Phenylmethanesulfonylfluoride
P-STAT3 Phosphorylated - signal transducer and activatorsof 
transcription 3
PVDF Polyvinylidenfluorid
RIP Receptor interacting protein
ROS Reactive oxygen s[ecies
rpm revolutions per minute
RT-PCR Reverse transcription – Polymerase chain reaction
SCFR Stem cell factor receptor
SDS Sodium dodecyl sulphate
SDS-PAGE Sodium dodecyl sulphate – polyacril amide gel 
electrophoresis
SDF-1 Stromal cell-derived factor 1 
sgp130 Soluble glycoprotein 130
sICAM-1 Soluble Intercellular Adhesion Molecule 1
sIL-6R Soluble Interleukin 6 Receptor
STAT1 Signal transducer and activator of transcription 1
STAT3 Signal transducer and activator of transcription 3
TACE TNF-α converting enzyme (ADAM17)
TAE Tris, Acetic acid, EDTA buffer
100
Appendix                                                                
TCR T-cell receptor
TEMED Tetramethylethylenediamine
TGF-α Transforming growth factor alpha 
TGF-β Transforming growth factor beta
Tie 1 Tyrosine  kinase  with  immunoglobulin-like  and  EGF-like 
domains 1
TLR Toll-like receptor
TRADD TNFR I associated death domain containing protein
TRAF 2 TNFR associated factor 2
TRAIL TNF-related apoptosis-inducing ligand 
TREM 1 Triggering receptor expressed on myeloid cells 1
Trk A Neurotrophic tyrosine kinase receptor type 1
TNF-α Tumor necrosis factor alpha 
TNFR I Tumor necrosis factor alpha receptor I
Tris-HCl tris-(hydroxymethyl)-aminomethane hydrochloric acid
Tyr tyrosine
V volt
VCAM-1 Vascular cell adhesion molecule 1 
VEGFα Vascular endothelial growth factor alpha 
VEGFR 1 Vascular endothelial growth factor receptor 1
VEGFR 2 Vascular endothelial growth factor receptor 2
VEGFR 3 Vascular endothelial growth factor receptor 3
WB Western Blot
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